

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



**PCT**Exp Mail EV335608188US  
USAN 10/601,080  
WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 47/48, C07H 15/26, 15/04, G01N 33/569, C07H 15/18</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/43356</b> <b>(43) International Publication Date:</b> 2 September 1999 (02.09.99)
<b>(21) International Application Number:</b> PCT/CA98/00817 <b>(22) International Filing Date:</b> 26 August 1998 (26.08.98) <b>(30) Priority Data:</b> 09/030,095 25 February 1998 (25.02.98) US PCT/CA98/00142 26 February 1998 (26.02.98) CA 60/095/673 7 August 1998 (07.08.98) US <b>(71) Applicant:</b> HSC RESEARCH DEVELOPMENT LIMITED PARTNERSHIP [CA/CA]; 555 University Avenue, Toronto, Ontario M5C 1X8 (CA). <b>(72) Inventors:</b> LINGWOOD, Clifford; 116 Kingsway Crescent, Toronto, Ontario M8X 2R9 (CA). MYLVAGANAM, Murugesapillai; Apartment #2701, 5 Massey Square, Toronto, Ontario M4C 5L6 (CA). <b>(74) Agents:</b> FRITZ, Joachim, T. et al.; Scott & Aylen, 1000 - 60 Queen Street, Ottawa, Ontario K1P 5Y7 (CA).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ANTIBIOTIC-LIGAND CONJUGATES AND METHODS OF USE THEREOF		
<b>(57) Abstract</b>  Methods for treating a glycolipid mediated state in a subject are described. An effective amount of at least one therapeutic compound represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent, is administered to a subject, such that treatment of the glycolipid mediated state occurs. Methods also include administering an effective amount of at least one therapeutic compound, or a pharmaceutically acceptable salt thereof, to a subject such that a disease state associated with an SLT is treated. Packaged pharmaceutical compositions for treating SLTs are described. The package includes a container for holding an effective amount of a pharmaceutical composition and instructions for using the pharmaceutical composition for treatment of SLT. The pharmaceutical composition includes at least one therapeutic compound for modulating an SLT in a subject.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



**ANTIBIOTIC-LIGAND CONJUGATES AND METHODS OF USE THEREOF****RELATED APPLICATION**

5           This application claims the benefit of priority under 35 U.S.C. 119(e) to U.S. provisional application Serial No. 60/039,160, filed February 26, 1997 and U.S. provisional application Serial No. 60/095,673, filed August 7, 1998. This application also claims priority to U.S. application Serial No. 09/030,095, filed February 25, 1998 and PCT application Serial No. CA98/00142, filed February 26, 1998. The contents of  
10 these cited applications are hereby incorporated by reference in their entirety.

**BACKGROUND**

15           Glycolipids have been shown to be involved with the early steps of the infectious process associated with several pathogens. For example, it is believed that oligosaccharide moieties coupled to ceramide lipid bases are used by the infectious agents as anchors or adsorption moieties for invasion of the host cells. Many bacteria and viruses have been found to use extracellular membrane components, such as  
20 glycolipids to access host cells.

          Pathogens include bacteria and viruses. For example, influenza A virus belongs to a family of negative strand RNA viruses called the *orthomyxoviridae*. They are a major cause of respiratory diseases in humans, of both epidemic and pandemic proportion. For years, Influenza A virus has continued to elude control by vaccines and  
25 chemotherapy due to antigenic variation (shift and drift). Antigenic shift is the sudden appearance of a different antigen subtype in a population while antigenic drift arises by mutation in the genes encoding for the antigen. Influenza A has been primarily contained by preparing effective vaccines based on predictions of future antigenic variation. Also, amantadine hydrochloride has been used in the prophylaxis and  
30 treatment of influenza A infections.

          Binding of influenza A virus to a cell is mediated by hemagglutinin (HA) antigen, which is a glycoprotein protruding from the virion envelope. HA is a non-covalently linked trimer in which each subunit consists of disulfide-linked HA1 and HA2 domains. HA1 is involved in receptor binding while HA2 is a transmembrane  
35 anchor. HA binds mainly to cell surface sialic acid (NeuAc) bonded to galactose by  $\alpha(2\rightarrow6)$  or  $\alpha(2\rightarrow3)$  linkages. Another example of a virus binding to a cell through glycolipids, is the binding of HIV through gp120 to GalC, a cell surface carbohydrate.

- 2 -

Shiga-like toxins (SLTs), a family of powerful, disease producing toxins, are produced by a common bacteria, *Escherichia coli*, found in humans and in animals. The term "SLT" is derived from the cytotoxic nature, structural and functional similarity to Shiga toxin which is a protein cytotoxin produced by *Shigella dysenteriae* type 1.

- 5 This *Shigella* serotype is responsible for the most severe cases of bacillary dysentery. SLTs are also known as verotoxins (VTs) because many of the serotypes that produce this toxin were originally characterized as being vero cell toxinogenic. The first member of the family of SLTs to be isolated was cytotoxic for African Green Monkey (Vero) cells and was originally called verotoxin. Further, SLT producing *E. coli* are a  
10 heterogeneous group of bacteria that belong to several different O:H:K serotypes; all having the ability to discharge one or more SLTs.

- SLTs are multimeric proteins composed of an enzymatic (A) subunit and multiple (B) subunits responsible for toxin binding to receptors on host tissues. The binding B oligomers of the SLTs recognize host cell globoseries glycolipid receptors  
15 containing at a minimum, the disaccharide unit of  $\alpha\text{Gal}(1-4)\beta\text{Gal}$  at the non-reducing terminus.

- Foods of animal origin are a major source of human infection by SLTs. Infants, young children and the elderly are the most susceptible to SLT infection, however, anyone who eats contaminated food is prone to infection. Additionally,  
20 infection can be spread by person-to-person transmission which can be especially problematic in day care centers and nursing homes.

- SLT-producing *E. coli* can also cause edema disease (ED) in swine. The often fatal disease occurs in weanling pigs, characterized by anorexia, edema of the eyelids and neurological abnormalities such as uncoordination and/or paralysis.

- 25 Antibiotics have been found to be contraindicated in the treatment of SLT producing *E. coli* infection in humans and pigs. Antibiotics often enhance toxin production by the bacteria. Treatment of SLT infection generally relies on management of the physiological complications of the infection, e.g. fluid and electrolyte imbalances.

- Although certain agents have been used to suppress infection of hosts by  
30 pathogens, there are limitations to their use. For example, the widespread use of antibiotics has increasingly led to the problem of resistant pathogens whose growth can no longer be inhibited by known antibiotics. Thus, the appearance of multi-drug resistant pathogens has prompted a search for new classes of compounds which are structurally and/or functionally different from existing drugs. Drugs having new  
35 mechanisms of action could be effective against resistant pathogens, where conventional drugs can no longer be used.

## SUMMARY OF THE INVENTION

5 This invention provides methods and compositions which are useful in the treatment of glycolipid mediated states, such as enteropathogenic and enterohemorrhagic *E. coli*. (EPEC and EHEC, respectively), e.g., verotoxin producing *E. coli*. (VTEC), or viruses e.g. *orthomyxoviridae*, e.g., influenza A, or HIV. Various pathogens, e.g., bacteria or viruses, invade host cells *via* attachment to or interaction with glycolipids which are associated with the host cell. The present invention serves to  
10 inhibit a pathogen from invading a host cell by providing a receptor molecule which has been modified with an active agent; the active agent in combination with the receptor molecule combine with the pathogen, thereby rendering it incapable of invading a host cell, or preferably, eradicating the pathogen.

The invention provides methods for treating a glycolipid mediated state  
15 in a subject by administering to the subject a therapeutically effective amount of a therapeutic compound, such that the glycolipid mediated state is treated. The therapeutic compound is represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent.

The present invention also provides methods of modulating interaction  
20 between a pathogenic microorganism and a glycolipid in a subject by administering to the subject a therapeutically effective amount of a therapeutic compound, such that interaction between a pathogenic microorganism and a glycolipid is modulated. The therapeutic compound is represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent.

25 The present invention provides methods for treating a state characterized by the presence of a shiga-like toxin in a subject by administering to a subject a therapeutically effective amount of a therapeutic compound, such that a state characterized by the presence of shiga-like toxin is treated. The therapeutic compound is represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is  
30 an active agent.

The present invention provides methods for treating a state characterized by the presence of a virus in a subject by administering to a subject a therapeutically effective amount of a therapeutic compound, such that a state characterized by the presence of virus is treated. The therapeutic compound is represented by the structure  
35 A-B, in which A is a glycomimetic receptor moiety and B is an active agent.

- 4 -

The present invention further provides compounds represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent. In one embodiment the glycomimetic receptor moiety includes an oligosaccharide moiety coupled to a ceramide lipid base. In a preferred embodiment, the glycomimetic receptor moiety is gangliotriaosyl ceramide galNAc $\beta$ 1-4gal $\beta$ 1-4glc cer (Gg<sub>3</sub>) or gangliotetraosyl ceramide gal $\beta$ 1-4galNAc $\beta$ 1-4glc cer (Gg<sub>4</sub>) and derivatives thereof. In another embodiment, the glycomimetic receptor moiety includes an oligosaccharide moiety coupled to a serine lipid base. In a preferred embodiment, the glycomimetic receptor moiety is glycosyl-N-acyl serine, globotriaosyl-N-acyl serine, or galactosyl-N-acyl serine or derivatives thereof. In still another embodiment, the glycomimetic receptor moiety includes an oligosaccharide moiety coupled to a sulfogalactosylceramide. Active agents are coupled to the glycomimetic receptor moiety and include antibiotics and carbocyclic compounds. Suitable antibiotics include penicillins, cephamas, cephalosporins. Suitable carbocyclic compounds include adamantyl, norbornyl or acridine derivatives.

The present invention provides pharmaceutical compositions which include a therapeutically effective amount of a therapeutic compound represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent and a pharmaceutically acceptable carrier. These pharmaceutical compositions are useful in treatment of glycolipid mediated states and for modulating interaction(s) between a pathogenic microorganism and a glycolipid in a subject.

The present invention also provides packaged therapeutic compositions for treating a glycolipid mediated state in a subject. The packaged therapeutic compositions include a container for holding a therapeutically effective amount of a therapeutic compound for treating a glycolipid mediated state in a subject and instructions for using the therapeutic composition for treating the glycolipid mediated state. The therapeutic compound is represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent.

The present invention further provides packaged therapeutic compositions for modulating interaction between a pathogenic microorganism and a glycolipid. The packaged therapeutic composition includes a container for holding a therapeutically effective amount of a therapeutic compound for modulating interaction between a pathogenic microorganism and a glycolipid in a subject and instructions for using the therapeutic composition for modulating interaction between the pathogenic microorganism and the glycolipid. The therapeutic compound is represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent.

- 5 -

The present invention further provides an assay for determining gp120 binding activity, by exposing a gp120 binding compound to gp120 such that an intermediate is formed. Unbound gp120 is removed from the intermediate and the intermediate is exposed to HIV sera. The binding of the HIV sera to the gp120 is  
5 detected thereby determining the gp120 binding activity of a gp120 binding compound.

The present invention further provides an assay for determining the inhibition between a Shiga-like toxin and its glycolipid receptor by providing a container coated with a glycolipid receptor and an inhibitor. The inhibitor and the glycolipid receptor are then mutually exposed and a Shiga-like toxin is provided. The binding of  
10 the Shiga like toxin to the receptor is analyzed thereby, determining the inhibition between a glycolipid receptor and a Shiga-like toxin.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B depict deacylation of a ceramide and coupling of an antibiotic to the deacylated ceramide.  
15

Figures 2A and 2B depict oxidation of the sphingosine double bond of glycolipids.

Figure 3 depicts coupling of an antibiotic with a deacylated ceramide.  
20

Figure 4 depicts a ceramide functionalized with multiple antibiotics.

Figure 5 represents functionalization of LysoPE.

Figure 6 depicts adamantyl glyconjugates of Gb<sub>3</sub>C and LC.  
25

Figure 7 depicts TLC analysis of serine and ceramide acids.

Figure 8 depicts mass spectra of serine and ceramide acids of behenic analogs of GalC.  
30

Figure 9 depicts mass spectra of serine and ceramide acids of palmitic analogs of GalC.

Figure 10 depicts fragmentation patterns of serine and ceramide acids.  
35

Figures 11A and 11B depict ion mass spectra of the serine acid from GM<sub>1</sub> and its production from GM<sub>1</sub>.

- 6 -

Figure 12 are western blots showing conjugate binding with gp120.

Figure 13A depicts inhibition of HIV coat protein gp120 binding to GalC  
5 and SGC.

Figure 13B shows the inhibitor compounds used in the gp120 inhibition  
assay.

Figure 14 shows glycolipid/lipid binding specificity.  
10

Figure 15 shows enhanced inhibitory activity of Gb<sub>4</sub>-ampicillin  
compared to ampicillin for uropathogenic *E. coli*.

Figure 16 shows inhibition of VT1 binding to Gb<sub>3</sub> phospholipid bilayer.  
15

Figure 17 shows results of a VT1 binding assay with inhibitors.

Figure 18 shows a TLC overlay of adamantyl conjugates of Gb<sub>3</sub>LC and  
GalC.  
20

Figure 19 depicts inhibition by N-adamentylacetyl Gb<sub>3</sub> derivatives.

Figure 20 depicts inhibition by Gb<sub>3</sub>S•NH<sub>2</sub><sup>c</sup>CONHAda vs. Gb<sub>3</sub>S•  
NHAc<sup>c</sup>CONHAda.  
25

Figure 21 shows the titration of the viral antigen.

Figure 22 shows the hemagglutination inhibition using SGC-liposomes.

Figure 23 shows the determination of the concentration at which SGC-  
derivatives do not lyse RBC.  
30

Figure 24 shows hemagglutination inhibition using SGC derivatives.

Figure 25 shows the TLC mobilities of various SGC derivatives.  
35

#### DETAILED DESCRIPTION

#### SUBSTITUTE SHEET (RULE 26)

The features and other details of the invention will now be more particularly described and pointed out in the claims. It will be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principle features of this invention can be employed in various embodiments without departing from the scope of the invention.

This invention pertains to methods and compositions which are useful in the treatment of glycolipid mediated states, such as enteropathogenic and enterohemorrhagic *E. coli*. (EPEC and EHEC, respectively), e.g., verotoxin producing *E. coli*. (VTEC) or viruses, e.g., HIV or *orthomyxoviridae*, i.e., influenza A.

The present invention pertains to methods for treating a glycolipid mediated state in a subject by administering to the subject a therapeutically effective amount of a therapeutic compound, such that the glycolipid mediated state is treated. The therapeutic compound is represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent. The methods of the invention can be used therapeutically to treat a subject afflicted by a pathogen or can be used prophylactically in a subject susceptible to pathogens. The methods of the invention are based, at least in part, on inhibiting or preventing interaction between the cell membrane surface and the pathogen.

The language "treating a glycolipid mediated state" or "such that the glycolipid mediated state is treated" is intended to include changes in a glycolipid mediated state or condition, as described *infra*, such that physiological symptoms in a subject can be significantly diminished or minimized. The language also includes control, prevention or inhibition of physiological symptoms or effects associated with a disease state associated with glycolipid mediated states. In one preferred embodiment, the control of the glycolipid mediated state or condition is such that the glycolipid mediated state or condition is eradicated. In another preferred embodiment, the control is selective such that a particular targeted glycolipid mediated state, e.g., a pathogen, is controlled while other cells and physiological flora which are not detrimental to the subject are allowed to remain substantially uncontrolled or substantially unaffected, e.g., lymphocytes, red blood cells, white blood cells, platelets, growth factors, etc. The term "glycolipid" as used in "glycolipid mediated state" is art recognized and is intended to include glycolipids, glycoproteins, and glycoamino acids which are associated with or found on the cell or viral surface.

The term "pathogen" is art recognized and is intended to include disease producing agents, such as organisms capable of causing disease in a subject, e.g., a

mammal, including, for example, bacteria, e.g., *Escherichia coli*, *Shigella dysenteriae*, viruses, e.g., HIV, *orthomyxoviridae*, influenza A, prions and fungi.

The term "glycolipid mediated state" is intended to include those disease states or conditions caused by or associated with one or more pathogens, e.g., bacteria or  
5 viruses. These glycolipid mediated states can include enterotoxins produced by pathogenic bacteria, e.g., *Escherichia coli*, and are known as shiga-like toxins (SLTs). The term is also intended to include those foreign entities produced by or associated with viruses, e.g., *orthomyxoviridae*.

Without wishing to be bound by theory, host cell receptors for adhesion  
10 of pathogens, such as bacteria and viruses, have often been found to comprise complex carbohydrates on the host cell surface. For the most part such carbohydrates have been found to be conjugated to lipid rather than protein, thus host/cell surface glycolipids play an important role as receptors for a variety of bacteria. Binding of influenza A virus to a cell is mediated by hemagglutinin (HA) antigen, which is a glycoprotein protruding  
15 from the virion envelope. HA is a non-covalently linked trimer in which each subunit consists of disulfide-linked HA1 and HA2 domains. HA1 is involved in receptor binding while HA2 is a transmembrane anchor. HA binds mainly to cell surface sialic acid (NeuAc) bonded to galactose by  $\alpha(2\rightarrow6)$  or  $\alpha(2\rightarrow3)$  linkages. The binding of HIV to the cell surface is mediated through an interaction between gp120 and GalC.

20 The major species recognized are glycolipids belonging to the ganglio series, globo series, glyco-sphingo series, or sulfatide. Thus, many pathogens have been shown to bind to the lipid-bound carbohydrate. The present invention pertains to ganglio series glycolipid recognition, since SLTs, such as verotoxin producing *E. coli* (VTEC) demonstrate a high binding affinity for these neutral glycosphingolipids and  
25 that this binding is distinct from that of enteropathogenic and commensal *E. coli* strains. The present invention also pertains to ganglio series glyco-sphingo recognition, since viruses, such as *orthomyxoviridae*, demonstrate a high binding affinity for these sulfogalactosylceramides.

The term "SLT" is art recognized and is intended to include cytotoxins  
30 similar in structure and function to Shiga toxin. The term is also intended to include verotoxins, based upon structural similarity to shiga toxins by sequencing of relevant genes and are often referred to as SLT1. Known SLTs include SLT-1, SLTII, SLTIII. Variants of SLTII (isolated and distinguished serologically on the basis of gene sequence or host specificity) include SLTII; vtx2ha; SLTIIvh; vtx2hb; SLTIIc; SLTIIvp,  
35 etc. The term encompasses the presently unknown SLTs or variants thereof that may be



discovered in the future. since their characterization as an SLT or variant thereof will be readily determinable by persons skilled in the art.

The term "*orthomyxoviridia*" is art recognized and intended to include those viruses associated with influenza, e.g. Influenza A, B, and C.

5       The term "subject" is intended to include mammals having a SLT, including one or more SLT related symptoms, or which are susceptible to pathogens producing SLTs. Examples of such subjects include humans, dogs, cats, pigs, cows, horses, rats and mice. The term "subject" is also intended to include mammals having a viral infection, including one or more viral related symptoms, or which are susceptible  
10 to viral infection.

The language "therapeutically effective amount" of a therapeutic compound, described *infra*, is that amount of a therapeutic compound necessary or sufficient to perform its intended function within a subject, e.g., treat a glycolipid mediated state, or a state characterized by the presence of a pathogen, e.g. an SLT or a  
15 virus, in a subject. An effective amount of the therapeutic compound can vary according to factors such as the amount of the causative agent already present in the subject, the age, sex, and weight of the subject, and the ability of the therapeutic compounds of the present invention to affect a state in the subject. One of ordinary skill in the art would be able to study the aforementioned factors and make a determination regarding the  
20 effective amount of the therapeutic compound without undue experimentation. An *in vitro* or *in vivo* assay also can be used to determine an "effective amount" of the therapeutic compounds described *infra*. The ordinarily skilled artisan would select an appropriate amount of the therapeutic compound for use in the aforementioned assay or as a therapeutic treatment.

25       A therapeutically effective amount preferably diminishes at least one symptom or effect associated with the glycolipid mediated state, SLT, or virus being treated by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects. In a most preferred embodiment, the therapeutically effective  
30 amount diminishes at least one symptom or effect by at least about 90%, more preferably by at least about 95%, and still most preferably 100%. Assays can be designed by one skilled in the art to measure the diminishment of such symptoms and/or effects. Any art recognized assays capable of measuring such parameters are intended to be included as part of this invention. For example, if blood in the stool is treated, then  
35 the diminishment of blood in the stool can be measured before and after treatment using an art recognized technique. Likewise, if hypertension is the state being treated, then the

- 10 -

pressure can be measured before and after treatment for measurement of diminishment of pressure using an art recognized technique.

The term "glycomimetic receptor moiety" is intended to include those compounds which are glycolipids, glycoproteins, glycoamino acids or derivatives thereof which are recognized by receptors on a cell surface, e.g., cell membrane or cell wall. The interaction between a glycomimetic receptor moiety and the receptor can include adhesion, ionic interactions, charged interactions and the like. Typically glycomimetic receptor moieties include an oligosaccharide moiety which is coupled to a serine or ceramide lipid base. Preferred glycomimetic receptor moieties are Gg3-gangliotriaosyl ceramide, GalNAc $\beta$ 1-4Gal $\beta$ 1-4 glucosyl ceramide, Gg4-gangliotetraosyl ceramide-Gal $\beta$ 1-3GalNAc $\beta$ 1-4Gal $\beta$ 1-4 glucosyl ceramide, glycosyl-N-acyl serine, globotriosyl-N-acyl serine, galactosyl-N-acyl serine, and sulfogalactosylceramides (See also, U.S. Patent No. 5,521,282, the contents thereof are incorporated by reference.) In certain embodiments, the receptor moiety is not a Gb3 or a Gb4 moiety. In other embodiments, the receptor moiety is not those described in U.S. Patent 5,466,681. In other embodiments, the glycomimetic receptor is a sulfated galactose attached to a sphingosine base.

For example, pathogen/host cell plasma membrane attachment is an important virulence trait for pathogens. Many specific pathogenic appendages, and adhesion molecules contained within such appendages, have been devised to maintain the close apposition of viral or prokaryotic and eukaryotic cell surface membranes. Apart from the obvious benefit of preventing pathogen removal by nonspecific shear forces, such interactions can provide the basis for the development of specific biological niches for particular pathogens. Such niches may involve the specific modification of the host cell plasma membrane to better accommodate the requirements of the pathogen. For enteropathogenic (EPEC) and enterohemorrhagic *E. coli* (EHEC, including VTEC), such parasitic interactions include modification of the host/cell plasma membrane architecture and submembrane reorganization due to complex signal transduction pathways between the attached organism and the host cytoskeletal network. This results in an 'attaching and effacing' (eae) lesion, in which local microvilli are lost, the host cell plasma membrane 'cups' the attached bacterium and actin is polymerized beneath the attachment site. Attachment *per se* can therefore cause significant changes in host cell physiology which of itself may induce pathology, e.g., in the case of gastrointestinal organisms, diarrhea.

Several bacterial products necessary for attachment have been identified, indicating the complexity of the virulence factor. Localized adhesion clusters

characteristic of EPEC on the surface of epithelial cells are dependent on the presence of a 57 mDa plasmid which contains the gene encoding the structural subunit of the bundle-forming pilus. Expression of the *eaeA* gene product 'intimin', a 94 kDa outer membrane protein, is involved in, but not sufficient for, EPEC/host cell adhesion to form the eae lesion. A second chromosomal gene, *eaeB*, has been identified which is also necessary for intimate host cell attachment. The expression of intimin is regulated by plasmid encoded factors which modulate virulence which further indicates the complexity of this system. Transfection of nonadherent *E. coli* with *eaeA* +/- *eaeB* does not result in the induction of epithelial cell adherence. *Eae* mutants still bind to host cells. Thus although *eae* is required for intimate host cell attachment, another factor may be required for initial host cell recognition and binding. A homologue of intimin has been identified in VTEC. The identification of the bundle forming pilus (bfp) in EPEC provides the mechanism for the initial host cell attachment of EPEC.

In the case of the viral pathogen, Influenzavirus A, attachment to the cellular surface is dependent on hemagglutinin (HA) antigen, a glycoprotein protruding from the virion envelope. HA is noncovalently linked trimer composed of three units each composed of a disulfide linked HA1 and HA2 subunits. HA2 structurally resembles to the F1 polypeptide of paramyxoviruses. HA1 is involved in receptor binding while HA2 is a transmembrane anchor. HA binds mainly to cell surface sialic acid (NeuAc) bonded to galactose by  $\alpha(2\rightarrow6)$  or  $\alpha(2\rightarrow3)$  linkages. The NA surface glycoprotein acts as an enzyme and allows the HA to come in to contact with the cellular membrane by acting as a hydrolase and lowering the pH surrounding the cell. This promotes the fusion process and allows the virus to invade the cell (Beers, R.F.(ed) *The Role of Immunological Factors in Infectious, Allergic, and Autoimmune Processes*, (Raven Press: New York, 1978) pp. 455-465.; Outlaw, M.C., Dimmock, N.J., *Epidemiol. Infect.* (1991), 106:205-220.).

The host cell receptors for adhesins of pathogens are believed to comprise complex carbohydrates on the host cell surface. For the most part such carbohydrates have been found to be conjugated to lipid rather than protein and play an important role as receptors for a variety of pathogens.

The common receptor activity of ganglio series glycolipids (primarily Gg3-gangliotriaosyl ceramide, GalNAc $\beta$ 1-4Gal $\beta$ 1-4 glucosyl ceramide and Gg4-gangliotetraosyl ceramide-Gal $\beta$ 1-3GalNAc $\beta$ 1-4Gal $\beta$ 1-4 glucosyl ceramide) for pathogenic bacteria was first demonstrated by studies by Krivan who noted that many respiratory pathogens bound to these glycolipids as demonstrated by TLC overlay *in vitro* (Krivan, H.C. *et al.* "Many Pulmonary Pathogenic Bacteria Bind Specifically to the

- 12 -

Carbohydrate Sequence GalNAc $\beta$ 1-4 Gal Found in Some Glycolipids" *PNAS* 85:6157-6161 (1988)). It has subsequently been established that *Helicobacter pylori* shares this binding specificity and an adhesin responsible for this binding has been purified and identified. Similarly, an adhesin responsible for related binding specificity for  
5 *Hemophilus influenza* has been isolated and purified. For *influenzavirus A*, the HA binds to sulfogalactosylceramide.

Pathogens which bind to Gg3 and or Gg4 *in vitro* also bind to the phospholipid, phosphatidyl ethanolamine (PE). Further, binding studies to cells which contain or lack PE, suggest that PE is a significant receptor to mediate pathogen  
10 attachment to eukaryotic cells. Not wishing to be bound by theory, it is believed that the binding to eukaryotic cell surface PE allows pathogens to preferentially target apoptotic cells. The loss of plasma membrane phospholipid asymmetry is an early marker of programmed cell death. Thus PE, normally located, for the most part, on the inner leaflet of the plasma membrane bilayer becomes available at the outer leaflet for  
15 pathogen binding. Preferential binding of pathogens to apoptotic cells may allow for the more efficient acquisition of nutrients by the microorganism. Apoptosis has been shown to play a significant role in the turnover of both the respiratory and gastrointestinal epithelia and thus attachment of one pathogens may facilitate that of another.

20 The term "active agent" is intended to include those compounds which inhibit, eliminate, or prevent enterotoxins such as SLTs or viruses from affecting host cells of the subject. For example, the active agent can be an antibiotic known to those skilled in the art. The term "antibiotic" is art recognized and is intended to include those substances produced by growing microorganisms and synthetic derivatives thereof,  
25 which eliminate or inhibit growth of pathogens and are selectively toxic to the pathogen while producing minimal or no deleterious effects upon the infected host subject. Suitable examples of antibiotics include, but are not limited to, the principle classes of aminoglycosides, cephalosporins, chloramphenicols, fuscidic acids, macrolides, penicillins, polymixins, tetracyclines and streptomycins. Preferably, the active agents of  
30 the invention include penicillins, cephams, cephalosporins and carbocyclic compounds.

The term "carbocyclic compound" is intended to include carbon cage compounds, such as adamantanes and norbornanes as well as acridines and derivatives thereof. In preferred embodiments, adamantanes and norbornanes can have one or more acetic acid substituents. Moreover, the term carbocyclic as used throughout the  
35 specification and claims is intended to include both "unsubstituted carbocycles" and "substituted carbocycles", the latter of which refers to carbocyclic moieties having

substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, 5 phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic 10 moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. Cycloalkyls can be further substituted, e.g., with the substituents described above. An "alkylaryl" moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)).

The term "aryl" as used herein, refers to the radical of aryl groups, 15 including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, benzoxazole, benzothiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Aryl groups also include polycyclic fused aromatic groups such as naphthyl, quinolyl, indolyl, and the like. Those aryl groups having heteroatoms 20 in the ring structure may also be referred to as "aryl heterocycles", "heteroaryls" or "heteroaromatics". The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, 25 phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic 30 or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., tetralin).

The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

35 Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to ten carbons,

- 14 -

more preferably from one to six carbon atoms in its backbone structure, even more preferably one to three carbon atoms in its backbone structure. Likewise, "lower alkenyl" and "lower alkynyl" have similar chain lengths.

5 The terms "alkoxyalkyl", "polyaminoalkyl" and "thioalkoxyalkyl" refer to alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., catenary oxygen, nitrogen or sulfur atoms.

10 The terms "polycyclyl" or "polycyclic radical" refer to the radical of two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, 15 alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylaryl amino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, 20 trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety.

The term "heteroatom" as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.

25 It will be noted that the structure of some of the compounds of this invention includes asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by 30 stereochemically controlled synthesis.

Examples of suitable carbocyclic moieties include substituted or unsubstituted hydrocarbons, e.g., adamantyl; norbornyl; or substituted or unsubstituted aromatic compounds such as naphthyl, quinolyl, acridinyl, tetrahydroacridinyl, anthracenyl, benzopyrenyl, and the like. Large carbocyclic cage moieties such as 35 porphyrins can also be used in the therapeutic compounds and methods of the invention. The carbocyclic moiety preferably has a steric bulk greater than the steric bulk of a

- 15 -

phenyl group; certain compounds in which C is a phenyl group have been found to be ineffective glycolipid mimics. The carbocyclic compounds most preferred are adamantane-3-acetic acid, norbornane, and 1,3-adamantanedi-acetic acid.

5 In certain embodiments of the invention, acridine and adamantane derivatives, as well as those listed in the paragraph *supra* are not included.

10 In a preferred embodiment, the carbocyclic moiety includes a portion which can be coupled to the glycomimetic receptor moiety, e.g., a carboxylic acid, amine or ester. Coupling can be effected by covalent, ionic, charge/charge interactions, etc. for attachment to the glycomimetic receptor moiety. For example aminoadamantanes or aminoacridines can be coupled to the carboxyl group of the oxidized sphingosine moiety. Likewise, carboxyladamantanes or carboxylacridines, e.g., carboxylic acids, can be coupled to the amino group of a deacylated glycolipid.

- 16 -

TABLE I

Organism	Binding to Gg <sub>3</sub> and Gg <sub>4</sub>
<i>Streptococcus pneumoniae</i>	+
<i>Streptococcus agalactiae</i> (Gp. B.)	+
<i>Branhamella catarrhalis</i>	+
<i>Chlamydia trachomatis</i>	+
<i>Chlamydia pneumoniae</i>	+
<i>Clostridium perfringens</i>	+
<i>Clostridium difficile</i>	+
<i>Staphylococcus aureus</i>	+
<i>Klebsiella pneumoniae</i>	+
<i>Borrelia burgdorferi</i>	+
<i>Haemophilus influenzae</i>	+
<i>Haemophilus parainfluenzae</i>	+
<i>Pseudomonas aeruginosa</i>	+
<i>Pseudomonas cepacia</i>	+
<i>Pseudomonas maltophilia</i>	+
<i>Neisseria gonorrhoeae</i>	+
<i>Neisseria meningitidis</i>	+
<i>Helicobacter pylori</i>	+
<i>Shigella dysenteriae</i>	+
<i>Shigella flexneri</i>	+
<i>Pasturella multocida</i>	+
<i>Coxiella burnetii</i>	+
<i>Mycobacterium tuberculosis</i>	+
<i>Mycobacterium avium-intracellulare</i>	+
<i>Salmonella typhimurium</i>	+
<i>Escherichia coli</i> ATCC 6883	+
<i>Escherichia coli</i> HB101/DH5a	+
<i>Bacillus subtilis</i>	
<i>Escherichia coli</i> K99	
<i>Listeria monocytogenes</i>	
<i>Vibrio cholera</i>	
<i>Mycoplasma</i> sp.	
<i>Streptococcus pyogenes</i>	



- 17 -

The phrase "associated with a pathogen" is intended to include, but is not limited to, those pathogens, e.g., bacteria, which are pathogenic to the host subject as listed in Table I. It also pertains to viruses and other non-bacterial pathogens, such as, for example, Influenza A.

5 In another aspect, the invention pertains to methods of modulating interaction between a pathogen and a glycolipid in a subject by administering to the subject a therapeutically effective amount of a therapeutic compound, such that interaction between a pathogen and a glycolipid is modulated. The therapeutic compound is represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent as discussed *supra*.  
10

The terms "modulate", "modulating" and "modulation" are intended to include preventing, eradicating, or inhibiting interaction between a pathogen and a glycolipid, e.g., in the context of the therapeutic methods of the invention. In another embodiment, the term modulate includes effects on SLTs, e.g., verotoxin, that  
15 diminishes the activity or production of the toxins(s). For example, the therapeutic compound can interact with the toxin(s) to inhibit proteolytic activity.

In yet another aspect, the present invention provides methods for treating a state characterized by the presence of a shiga-like toxin (SLT) in a subject by administering to a subject a therapeutically effective amount of a therapeutic compound,  
20 such that a state characterized by the presence of shiga-like toxin is treated. The therapeutic compound is represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent.

The language "state characterized by the presence of a SLT" is intended to include those diseases, disorders or conditions which have been associated with a toxin, e.g., an enterotoxin, produced by a pathogen, e.g., bacteria, in that the pathogen is  
25 directly or indirectly a causative agent of the disease, disorder or condition. The pathogen does not have to be the sole causative agent of the disease, disorder or condition but be merely responsible for causing some of the symptoms typically associated with the disease, disorder, or condition being treated. The pathogen can be  
30 the causative agent alone or at least one other agent can be involved in the state being treated. Examples include uncomplicated diarrhea, bloody diarrhea, hemorrhagic colitis, hemolytic uremic syndrome (HUS), fluid electrolyte imbalances, anemia, renal failure and/or hypertension manifested by the presence of symptomatic responses, such as gastritis, (*Salmonella typhi*), food poisoning (*E. coli* O157:H7), bacillary dysentery  
35 (*Shigella dysenteriae*), pneumonia (*Pseudomonas aeruginosa*) and cholera (*Vibrio cholerae*). Preferred examples include those symptoms associated with *E. coli*.

- 18 -

Moreover, Hemolytic uremic syndrome (HUS) is the primary cause of acute pediatric renal failure. The majority of cases occur in children under three years of age but HUS may also occur in the elderly and occasionally in adults. HUS is defined by a triad of clinical symptoms: thrombocytopenia, hemolytic anemia and microvasculopathy. Epidemiological studies within the last 15 years have established that HUS is caused primarily by gastrointestinal infection with verotoxin producing *E. coli*. (VTEC). Gastrointestinal infection with VTEC, primarily of the O157 H7 serotype, can cause hemorrhagic colitis (HC) which may progress to HUS. In these pathologies, systemic verotoxin targets the endothelial cells within the microvasculature of the gastrointestinal tract and the pediatric renal glomerulus. VTEC are not believed to be invasive and thus the clinical pathology is the result of translocation of verotoxin across the gastrointestinal barrier to the systemic circulation. Structural studies indicate that the verotoxin receptor glycolipid (globotriaosyl ceramide-Gb<sub>3</sub>) is not present on the gastrointestinal epithelial cell surface and therefore the mechanism by which the toxin translocates from the GI tract is essentially unknown. Studies *in vitro* and in animal models however indicate that the attachment of the verotoxin producing *E. coli* organism to the host epithelial cell membrane may be intimately involved in the mechanism by which the toxin translocates. Similarly, attachment of the organism to the gastrointestinal host cell plasma membrane is an important virulence trait in the induction of diarrhea.

Verotoxins (or Shiga like toxin) comprise a family of subunit toxins which target the glycolipid globotriaosyl ceramide (Gb<sub>3</sub>) expressed on the surface of sensitive cells. The language "treating or treatment of the state characterized by the presence of an SLT" is intended to include the alleviation of or diminishment of at least one symptom typically associated with the state. The treatment also includes alleviation or diminishment of more than one symptom. Preferably, the treatment cures, e.g., substantially eliminates, the symptoms associated with the state.

In one aspect, the present invention pertains to compounds represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent. Synthesis of the compounds represented by the structure A-B can be accomplished by various approaches detailed as follows (For example, see also Sakac, D. *et al.* "Purification of the Testicular Galactolipid 3' Phosphoadenosine 5' Phosphosulfate Sulfotransferase" J. Biol. Chem. 267:1655-1659 (1992); Lingwood C.A. "The Production of Glycolipid Affinity Matrices by Use of Heterobifunctional Crosslinking Reagents" J. Lipid Res. 25:1010-1012 (1984); Lingwood C.A. and Taylor T. "Synthesis and Use of Galactolipid Sulfotransferase Substrate-analogue Affinity


Probes" *Biochem. Cell Biol.* **64**:631-637 (1986) and Thong B. *et al.* "Anti-digoxin Antibodies: Lack of Specificity of Current Antisera. Preparation of New, Specific Antibody which Recognizes the Carbohydrate Moiety of Digoxin" *Clin. Chem.* **31**:1635-1631 (1985); and Boulanger, J. *et al.* *Anal. Biochem.* **217**:1-6 (1994)).

5           The expression of surface adhesins or toxins, e.g., VTEC, specific for Gg3/Gg4 or PE allows for the accumulation of a lipid receptor-analog/antibiotic conjugate at the bacterial cell surface. Antibiotics which are active at the pathogenic surface are coupled to derivatives of either Gg3/Gg4,SGCor PE. These "receptocides" are bound by the bacterium and this accumulation results in the more efficient inhibition  
10 of pathogen membrane assembly. In addition, these receptocides function as anti-adherents to prevent the attachment of the pathogen to host cells. Furthermore, any development of resistance due to the loss of such adhesin species can be avoided since loss of the adhesin, in order to avoid binding of the receptocide, can also result in the loss of ability to bind to host cells. Moreover, the lipid binding specificity is restricted  
15 to pathogens and thus would spare the beneficial commensal *E. coli* strains, in contrast to broad spectrum antibiotics.

          In one method, Gg4 can be prepared from GM1 and Gg3 from GM2 ganglioside (both commercially available) by mild acetic acid hydrolysis to remove the sialic acid. For example, Gg4 is first treated with aqueous base when the aminosugar is  
20 preferentially deacylated (since the lipid moiety is sequestered in micelles) and the free amine is alkylated, e.g., dimethylated. The ceramide of the dimethyl Gg4 is then deacylated with alcoholic base and the free amine of the sphingosine base is coupled, for example, to the carboxyl group of an antibiotic, for example N-acetyl penicillin, as shown in Figures 1A and 1B (Schemes 1A and 1B).

25           In a second method, oxidative cleavage of the double bond in the sphingosine of glycosphingolipids affords a carboxylic acid ("glycosphingosinic" acid) derivative for coupling to amino containing antibiotics. Oxidation of sphingosine double bond of glycolipids by ozonolysis has been previously described. This method can be greatly improved by the use of KMnO<sub>4</sub> oxidation in the presence of sodium periodate and tert-  
30 butanol. In addition, the oxidation can be performed in both neutral and basic solutions to yield different oxidation products as shown in Scheme A below. R represents groups such as hydrogen, alkyl ketones, e.g., methyl ketone, aryl ketones, e.g., phenyl ketone, alkyl or aryl esters, e.g., t-butyl ester and other acyl groups.

- 20 -




SCHEME A

In a preferred method, depicted in Figures 2A and 2B (Schemes 2A and 2B), the oxidation procedure is carried out in a neutral tertiary butyl alcohol solution and utilizes catalytic amounts of KMnO<sub>4</sub> (plus a regeneration system to prevent MnO<sub>2</sub> precipitation). This method provides the advantages that i) tertiary butyl alcohol is not liable to KMnO<sub>4</sub> oxidation, ii) lack of precipitation prevents product loss by adsorption. The procedure affords high yields (40-80%) of the ceramide oligosaccharide as the single product.

In another preferred method, the allylic alcoholic function as a whole undergoes oxidation as depicted in Scheme B. This oxidation procedure utilizes catalytic amounts of KMnO<sub>4</sub> (plus a regeneration system to prevent MnO<sub>2</sub> precipitation) in a basic solution of tertiary butyl alcohol. This procedure affords high yields (40-80%) of the serine oligosaccharide.


- 21 -

**SCHEME B**


In another embodiment, the glycolipid is first deacylated to remove the fatty acid and the free amine is alkylated, e.g., methylated resulting in the dimethylation of the aminosugar in Gg<sub>3</sub>. The sugar residues are then acetylated prior to oxidation of the sphingosine double bond as in Figures 2A and 2B (Schemes 2A and 2B) and Scheme B.

The carboxylic acid can be activated using procedures known in the art, for example, N-OH succinimide and coupled, using dicyclohexylcarbodiimide, to the amino function of an antibiotic as shown in Figure 3 (Scheme 3, shown for Gg<sub>3</sub>) and Scheme C. EDAC is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The hydroxyl groups can be regenerated by deacetylation using triethylamine base.

- 22 -

**Note:**R<sub>1</sub> = HR<sub>2</sub> = Acyl for natural GSLs

For deacyl GSLs

R<sub>2</sub> = H, CH<sub>3</sub>CO, PhCO, COOtBu

SCHEME C


- 23 -

Preferred embodiments include monoalkylated, dialkylated, monoarylated or diarylated deacylated glycolipids described by the above procedures. For example, the resultant amino functionality of the deacylated glycolipid can be  
5 treated with alkylating or arylating agents known in the art. Preferably, the amine is dialkylated or diarylated with lower alkyl groups. e.g., methyl, ethyl, propyl, or aryl groups whose steric bulk do not interfere with the bioreactivity of the resultant conjugate, e.g., benzyl, benzoyl, aryl.

10 In a preferred embodiment, the glycomimetic receptor moiety, A, can be a sulfated saccharide. The sphingosine moiety of a SGC can be left intact or oxidized to yield an amine. The amine can then be coupled to a rigid hydrophobic moiety, such as a norbornyl or adamantyl group. The sphingosine chain can be further oxidized yielding either a ceramide or serine derivative (Scheme D).

- 24 -

## SCHEME D




SUBSTITUTE SHEET (RULE 26)




It is possible to go beyond these initial receptocides and synthesize species which have several (including different) antibiotics coupled to a single carbohydrate (shown in Figure 4)(Scheme 4)). For example, the amino crosslinker (tertiary butylamine) can be added in large excess to the carboxyl Gg4 derivative and coupled using dicyclocarbodiimide. After purification, the triamino Gg4 can then be coupled to antibiotic(s) as discussed above.

Additionally, therapeutic compounds depicted below can be prepared by known coupling reactions, e.g., etherification reactions, where X, Y and R represent soluble Gg3 or Gg4 mimics.



- 26 -



25 Derivatization of the amino group of PE may result in the loss of pathogenic receptor activity. However, lyso-PE in which the C3 position which contains an ether linked fatty acid and a free hydroxyl group which is present at C2 and is strongly bound by some SLTs, e.g., VTEC. Accordingly, a strategy depicted in Figure 5 (Scheme 5) demonstrates that coupling of an antibiotic species to the C2 OH of lyso-PE generates PE/antibiotic receptocides which can selectively target SLTs as opposed to

30 commensal GI *E. coli* strains. The procedure involves protecting the primary amine, followed by oxidation of the glycerol alcohol to give the corresponding ketone. Coupling of an amino antibiotic by reductive amination and finally deprotection of the amine of ethanolamine results in the final PE receptoside.

35 The structures of the receptocides made can be determined by FAB mass spectrometry, proton NMR as well as those techniques known to persons of skill in the art.

- 27 -

It is believed that the availability of adhesin targeted antibiotics should allow the administration of pathogenicidal doses which represent significantly lower antibiotic doses when considered on a molar basis. The binding of the receptocides by the SLTs, e.g., VTEC, result in the concentration of the antibiotic at the pathogen surface for more efficient inhibition of membrane assembly. Judicious selection of antibiotics with activity against SLTs may result in the generation of new potent treatments for the effective and selective elimination of SLTs from the subject, e.g., human, GI tract.

The topology of the adhesins on the SLTs, e.g., VTEC, surface may not optimally correspond to the surface location of the antibiotic binding proteins (transpeptidases) necessary for antibiotic inhibition of pathogen membrane assembly. Therefore, the introduction of an appropriate space group between the receptor and the antibiotic may further improve antibiotic efficacy by optimizing the matching of adhesin and antibiotic-binding-protein topology. Suitable spacer groups are known in the art and can include anhydrides, haloalkylamines and the like.

In another aspect, the present invention pertains to pharmaceutical compositions which include a therapeutically effective amount of a therapeutic compound represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent, described *supra*, and a pharmaceutically acceptable carrier. These pharmaceutical compositions are useful in treatment of glycolipid mediated states and for modulating interaction(s) between a pathogenic microorganism and a glycolipid in a subject.

The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a compound(s) of the present invention within or to the subject such that it can perform its intended function. Typically, such compounds are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol;

- 28 -

polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances  
5 employed in pharmaceutical formulations.

As set out above, certain embodiments of the present compounds can contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids. The term "pharmaceutically acceptable salts" in this respect, refers to the relatively non-  
10 toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate,  
15 bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, e.g., Berge et al. (1977) "Pharmaceutical Salts", *J. Pharm. Sci.* 66:1-19).

In other cases, the compounds of the present invention may contain one  
20 or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically acceptable salts" in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared *in situ* during the final isolation and purification of the compounds,  
25 or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.  
30 Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.

The term "pharmaceutically acceptable esters" refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters  
35 can be prepared *in situ* during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a

- 29 -

suitable esterifying agent. Carboxylic acids can be converted into esters *via* treatment with an alcohol in the presence of a catalyst. Hydroxyl containing derivatives can be converted into esters *via* treatment with an esterifying agent such as alkanoyl halides. The term is further intended to include lower hydrocarbon groups capable of being solvated under physiological conditions, e.g., alkyl esters, methyl, ethyl and propyl esters. (See, for example, Berge et al., *supra*.)

The invention further contemplates the use of prodrugs which are converted *in vivo* to the therapeutic compounds of the invention (see, e.g., R.B. Silverman, 1992, "The Organic Chemistry of Drug Design and Drug Action", Academic Press, Chp. 8). Such prodrugs can be used to alter the biodistribution (e.g., to allow compounds which would not typically enter the reactive site of the protease) or the pharmacokinetics of the therapeutic compound. For example, a carboxylic acid group, can be esterified, e.g., with a methyl group or an ethyl group to yield an ester. When the ester is administered to a subject, the ester is cleaved, enzymatically or non-enzymatically, reductively or hydrolytically, to reveal the anionic group. An anionic group can be esterified with moieties (e.g., acyloxymethyl esters) which are cleaved to reveal an intermediate compound which subsequently decomposes to yield the active compound. In another embodiment, the prodrug is a reduced form of a sulfate or sulfonate, e.g., a thiol, which is oxidized *in vivo* to the therapeutic compound. Furthermore, an anionic moiety can be esterified to a group which is actively transported *in vivo*, or which is selectively taken up by target organs. The ester can be selected to allow specific targeting of the therapeutic moieties to particular reactive sites, as described below for carrier moieties.

Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

Formulations of the present invention include those suitable for oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral

- 30 -

administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.

Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.

In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate; and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; absorbents, such as kaolin and bentonite clay; lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the

- 31 -

pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

5           A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be  
10 made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

          The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and  
15 other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by  
20 incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of  
25 embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

          Liposomes are microscopic spherical membrane-enclosed vesicles or sacks (20-30  $\mu\text{m}$  in diameter) made artificially in the laboratory using a variety of  
30 methods. Within the scope of the present invention, the liposomes should be non-toxic to living cells and they should deliver the contents, in this case a compound of the invention to the infected area. The liposomes according to the present invention may be of various sizes and may comprise either one or several membrane layers separating the internal and external compartments. An important element of the present invention is  
35 that a sufficient amount of compound be sequestered so that a relatively low concentration of compound is required for delivery to the infected area and further that

- 32 -

the liposome be resistant. Liposome structures according to the present invention includes small unilamellar vesicles (less than 250 angstroms in diameter), large unilamellar vesicles (greater than 500 angstroms in diameter) and multilamellar vesicles depending upon the quantity of compound required to be encapsulated. In the present invention, small unilamellar vesicles are preferred since the compound, according to the present invention is only required in low concentrations.

The liposomes may be made from natural and synthetic phospholipids, and glycolipids and other lipids and lipid congeners; cholesterol, cholesterol derivatives and other cholesterol congeners; charged species which impart a net charge to the membrane; reactive species which can react after liposome formation to link additional molecules to the lysome membrane; and other lipid soluble compounds which have chemical or biological activities.

A general discussion of the liposomes and liposome technology can be found in an article entitled, "Liposomes" by Marc J. Ostro, published in *SCIENTIFIC AMERICAN*, January 1987, Vol. 256, pp. 102-111 and in a three volume work entitled, "Liposome Technology" edited by G. Gregorriadis, 1984, published by CRC press, Boca Raton, Fla. the pertinent portions of which are incorporated herein by reference.

Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable



- 33 -

nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.

5           Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions,  
10   gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils,  
15   waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally  
20   contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption  
25   enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.

Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.

30           Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may  
35   contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

- 34 -

Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.

The preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred.

- 35 -

The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

The phrases "systemic administration," "administered systematically," "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.

Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that

- 36 -

required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous and subcutaneous doses of the compounds of this invention for a patient, when used for the indicated analgesic effects, will range from about 0.0001 to about 200 mg per kilogram of body weight per day, more preferably from about 0.01 to about 150 mg per kg per day, and still more preferably from about 0.2 to about 140 mg per kg per day.

If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.

While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.

In still another aspect, the present invention pertains to packaged therapeutic compositions for treating a glycolipid mediated state in a subject. The packaged therapeutic compositions include a container for holding a therapeutically effective amount of a therapeutic compound for treating a glycolipid mediated state in a subject and instructions for using the therapeutic composition for treating the glycolipid mediated state. The therapeutic compound is represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent.

In one aspect, the present invention pertains to packaged therapeutic compositions for modulating interaction between a pathogen and a glycolipid. The packaged therapeutic composition includes a container for holding a therapeutically effective amount of a therapeutic compound for modulating interaction between a pathogen and a glycolipid in a subject and instructions for using the therapeutic composition for modulating interaction between the pathogen and the glycolipid. The therapeutic compound is represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent.

Since pathogenic *E. coli* provide the basic etiology of states characterized by the presence of SLTs, e.g., both HC and HUS, it was initially considered that antibiotic treatment would be an effective therapy for these microvascular diseases. Clinical experience suggested that this was not the case. Indeed antibiotic treatment may exacerbate rather relieve symptoms. Studies have indicated that use of

- 37 -

"appropriate" antibiotics (ampicillin, amoxycillin) is associated with a lack of progression to HUS without significant worsening of the diarrheal disease. However, use of "inappropriate" antibiotics is associated with higher incidence of HUS in shigellosis

5 Adverse antibiotic effects may be due to two factors: firstly that at the first appearance of SLT symptoms requiring medical attention (blood in stools), the pathogenic organisms in the stool are declining in number. Thus the major effect of antibiotics given at this time will be to remove commensal organisms which likely have a protective effect. Secondly, it has been proposed that antibiotic treatment may induce  
10 pathogenic lysis and thereby release a bolus of intracellular SLTs from dying organisms. In this regard it has been shown *in vitro* that treatment of pathogenic strains with subinhibitory concentrations of trimethoprim-sulfamethoxazole did in fact increase the release of SLTs.

Advantages of the invention include i) early diagnosis of SLTs, so that  
15 receptocide therapy can be initiated prior to the production of significant levels of SLTs, e.g., verotoxin, within the GI tract and ii) methods to target antibiotics to the pathogenic microorganism and not commensal GI organisms.

Several rapid ELISAs (including a receptor based ELISA (Verotest™) are now in clinical trials for detection of VT in stools (Donohue-Rolfe, A. *et al.* "Enzyme-linked Immunosorbent Assay for Shigella Toxin" J. Clin. Microbiol. 24:65-68 (1986)  
20 and Basta, M. *et al.* "Sensitive Receptor-specified Enzyme-linked Immunosorbent Assay for Escherichia coli Verocytotoxin" J. Clin. Microbiol. 127:1617-1622 (1989)). Measurement of SLTs in stools has been established as the most effective means of diagnosing SLT infections and the availability of rapid automated ELISAs will allow  
25 screening of diarrhea cases. With diagnosis of SLT induced diarrhea, receptocide treatment prior to overt pathological lesions, becomes feasible. Indeed, with this advance in diagnosis, development of novel treatment regimes becomes mandatory.

The invention is further illustrated by the following examples which in no way should be construed as being further limiting. The contents of all references and  
30 published patent applications, cited throughout this application are hereby incorporated by reference. It should be understood that the models used throughout the examples are accepted models and that the demonstration of efficacy in these models is predictive of efficacy in humans.

## EXPERIMENTAL

MATERIALS AND METHODS5                    MATERIALS:

Solvents - dichloromethane (DCM), *tert*-butyl alcohol (<sup>t</sup>BuOH), *iso*-propyl alcohol (<sup>i</sup>PrOH), 1,2-dichloro ethane (DCE), pyridine (Py), diethyl ether (Et<sub>2</sub>O), benzene (Bz), methanol (M), chloroform (C), acetonitrile (AcCN) and acetone (A) - were purchased from either Caledon (Georgetown, Ontario) or Aldrich (Milwaukee, WI) and ethanol (EtOH) from Commercial Alcohols Inc. (Brampton, Ontario). Reagents were purchased from the following suppliers: Caledon - trifluoroacetic anhydride, K<sub>2</sub>CO<sub>3</sub>, sodium cyanoborohydride (NaBH<sub>3</sub>CN), triethylamine (Et<sub>3</sub>N); Aldrich - 37% aqueous formalin solution, 0.5N H<sub>2</sub>SO<sub>4</sub> solution, trichloroacetic anhydride, acetic anhydride, diphenyl succinimidyl phosphate (PNHS); BDH (Toronto, Ontario) - ANALAR KMnO<sub>4</sub>, ANALAR NaHSO<sub>3</sub>, 30% H<sub>2</sub>O<sub>2</sub>; Sigma (St. Louis, MO) - dimethylsulfoxide (DMSO), oleic anhydride (C<sub>36</sub>H<sub>66</sub>O<sub>3</sub>), erucic anhydride (C<sub>44</sub>H<sub>82</sub>O<sub>3</sub>), 4-chloro-1-naphthol; Fluka - bissuccinimidyl oxalate (OxNHS) and from Fisher Scientific (Unionville, Ontario) - *meta*-NaIO<sub>4</sub>. Chromatographic materials - Silica gel, TLC, HPTLC and aluminum backed nanosilica plates (alugram NanoSIL GI UV<sub>254</sub>, Macherey & Nagel) - were supplied by Caledon. Reverse phase C-18 cartridges were obtained from Waters (Mississauga, Ontario) and molecular sieves, 4Å from Fisher. Centricon-30 centrifugal concentrators were purchased from Amicom®

Solvents were dried by storing over activated (~120° C for 16 hrs) molecular sieves. Solvent systems are given in volume ratios. Crown ether (10 g) was recrystallized from a hexane (4 to 5 mL) solution at -20° C, washed with cold (-20° C) hexanes (1 mL) and dried at 40° C under a stream of N<sub>2</sub>.

BSA (99%, essentially fatty acid free) was purchased from Sigma. Recombinant gp120 was purchased from Intracell (CA), anti-human IgG horse radish peroxidase conjugate from Bio-Rad and human sera from HIV patients containing anti-gp120 antibodies was a gift from Dr. S. Read, Division of Infectious Disease, HSC.

Glycosphingolipids:

Globotetraosyl ceramide, Gb<sub>4</sub>•C, Globotriaosyl ceramide, Gb<sub>3</sub>•C and Lactosyl ceramide, Lac•C were purified from human kidney (Boyd, B. and Lingwood, C. A. (1989) *Nephron* 51, 207-210) and Forssmann, Gb<sub>5</sub>•C was purified from sheep

- 39 -

blood (Ziolkowski, C. H., Fraser, B. A. and Mallette, M. F. (1975) *Immunochemistry* 12, 297-302) and monosialylganglioside, GM<sub>1</sub>•C was purified from bovine brain (Yamakawa, T., Irie, R. and Iwanaga, M. (1960) *J. Biochem.* 48, 490-497) according to previously published procedures. Galactocerebroside, Gal•C was purchased from Sigma. Gangliotetraosyl ceramide, Gg<sub>4</sub>•C was prepared by acid hydrolysis of GM<sub>1</sub>•C with 1 M acetic acid at 80° C for 1 hour (Head, S., Ramotar, K. and Lingwood, C. A. (1990) *Infect. Immun.* 58, 1532-1537). De-Nacylated derivatives, Gb<sub>3</sub>•S, Gal•S (phychosine) were prepared by saponification at 102° C with 1 M methanolic NaOH for 3 hours (Head *et al.* (1990)).

### METHODS

#### Synthesis of NN-dimethylated Derivatives: Gb<sub>3</sub>•SNNMe<sub>2</sub> (Galα1→4 Galβ1→4Glcβ1→sphingosineNNMe<sub>2</sub>), Gal•SNNMe<sub>2</sub> (Galβ1→sphingosineNNMe<sub>2</sub>)

To a solution of 1 mg of deacylated GSL (approximately, 2 μmol for monosaccharide, 1.5 μmol for disaccharide and 1.25 μmol for trisaccharide deacyl GSLs) in methanol (0.5 mL), 40 μL of 37% aqueous formaldehyde solution (15 mg of formaldehyde, 500 μmol) and 100 μL of 0.32 M methanolic solution of NaCNBH<sub>3</sub> (prepared by dissolving 20 mg of NaCNBH<sub>3</sub> in 1 mL of dry MeOH) were added (Borch, R. F., Bernstein, M. D. and Durst, H. D. (1969) *J. M. C. S.* 93, 2897-2904; Means, G. E. and Feeney, R. E. (1995) *Anal. Biochem.* 224, 1-16). After stirring, the reaction mixture for 16 hours at room temperature (25° C), methanol was removed under N<sub>2</sub> and the remaining solid was dissolved, by sonication, in 5 mL of distilled water. The resulting suspension was passed through a C-18 reverse phase cartridge; washed with 20 mL of water and eluted with 20 mL of methanol. The yield of methylated product was >90% by TLC. TLC showed that the methylated compound has a reduced mobility compared to the deacyl forms. The R<sub>f</sub> values for Gal•S and Gal•SNNMe<sub>2</sub> are 0.80 and 0.75 in CHCl<sub>3</sub>:MeOH:H<sub>2</sub>O; 60:35:8 or 0.38 and 0.31 in CHCl<sub>3</sub>:MeOH:H<sub>2</sub>O; 65:25:4 respectively. Positive ion mass spectroscopic data, (m/z): Gal•SNNMe<sub>2</sub>, FAB, 489, (M+H); Gb<sub>3</sub>•SNNMe<sub>2</sub>, ES, 814 (M+H), 836 (M+Na).

Synthesis of N-trihaloacetyl Derivatives: Gal•SNTfa  
(Galβ1→sphingosineNTfa), Gal•SNTca (Galβ1→sphingosineNTca)

5 Acetylating reagents. N-acetyl imidazole and N-trihaloacetyl imidazole, were prepared by adding a DCM solution of anhydride - for example (CL<sub>3</sub>CO)<sub>2</sub>O (0.85 g, 2.7 mmol) dissolved in DCM (2mL) and the resulting solution was divided in 3 portions and added at 15 minute intervals, to an imidazole (0.41 g, 6.0 mmol) suspension in DCM (3 mL). The reaction mixture was stirred for 2 hours and was  
10 assumed to be approximately a 0.5 M solution of the imidazole derivative.

A solution of the imidazole derivative was added to a DCM suspension of GSL•S (1 mg/mL). For example, N-trichloroacetyl imidazole solution (20 μL, 10 μmol) was added to a suspension of Gal•S (3 mg in 3 mL of CH<sub>2</sub>Cl<sub>2</sub>, 6 μmol), and the reaction was monitored by TLC (CHCl<sub>3</sub>:MeOH:H<sub>2</sub>O; 70:30:2). Appearance of many orcinol  
15 positive products suggested some degree of acylation of OH groups. Once the GSL•S was consumed, DCM was removed under a stream of N<sub>2</sub>, a solution of Et<sub>3</sub>N:MeOH:H<sub>2</sub>O; 2:6:10 (0.5 mL/mg of GSL) was added and incubated at RT and the reaction was monitored every 30 minutes by TLC (CHCl<sub>3</sub>:MeOH:H<sub>2</sub>O; 70:30:2). Once  
20 all the orcinol positive species collapsed to a single band, the reaction mixture was dried under a stream of N<sub>2</sub>, redissolved in DCE and loaded on to a silica column (0.5 X 6 cm, in DCE) and eluted with CHCl<sub>3</sub>:MeOH; 98:2 (batch elution, 25 mL) and then with CHCl<sub>3</sub>:MeOH:H<sub>2</sub>O; 80:20:2 (10, 3 mL fractions were collected). The estimated product yield by TLC was >90%.

25 Synthesis of Gal•Coleic (Galβ1→sphingosineN-oleic) and Gal•Curecic  
(Galβ1→sphingosineN-urecic) Homologues:

To a solution Gal•S (2 mg, 4 μmol) in dry pyridine (2 mL) an excess of the anhydride (approximately 5 mg, corresponding to 9 μmol and 8 μmol for oleic and  
30 erucic anhydrides respectively) was added and stirred at 37° C for 18 hours. Pyridine was removed under a stream of N<sub>2</sub> and the residue was treated with 1 M methanolic NaOH (2 mL) for 5 hours at 25° C, neutralized with 1 M HCl (2 mL), diluted with water (5 mL), the aqueous phase extracted three times with 5 mL portions of Et<sub>2</sub>O and the combined extracts were dried. The crude extract was then dissolved in DCM (1mL) and  
35 loaded on to a silica column (0.5 X 10 cm in CHCl<sub>3</sub>:MeOH; 98:2). The free fatty acids were eluted with DCE:is<sup>o</sup>PrOH; 85:15 (20mL) and the product was eluted with



- 41 -

CHCl<sub>3</sub>:MeOH:H<sub>2</sub>O; 80:20:2 (6, 4 mL fractions were collected). The estimated yield by TLC was >95%.

Synthesis of Peracetylated Derivatives: Gal(OAc)<sub>4</sub>C(OAc),  
Gal(OAc)<sub>4</sub>•C<sub>oleic</sub>(OAc), Gal(OAc)<sub>4</sub>•C<sub>urecic</sub>(OAc), Lac(OAc)<sub>7</sub>C(OAc),  
Gb<sub>3</sub>(OAc)<sub>10</sub>C(OAc), Gb<sub>4</sub>(OAc)<sub>12</sub>C(OAc), Gg<sub>4</sub>(OAc)<sub>12</sub>C(OAc),  
Gb<sub>5</sub>(OAc)<sub>14</sub>C(OAc), GM<sub>1</sub>(OAc)<sub>16</sub>C(OAc)<sub>1</sub>, Gal(OAc)<sub>4</sub>•SNTfa(OAc),  
Gal(OAc)<sub>4</sub>•SNTca(OAc), Gal(OAc)<sub>4</sub>•SNAc(OAc), Gal(OAc)<sub>4</sub>•SNNMe<sub>2</sub>-  
(OAc), Gb<sub>3</sub>(OAc)<sub>10</sub>•SNAc(OAc), and Gb<sub>3</sub>(OAc)<sub>10</sub>•SNNMe<sub>2</sub>(OAc)

Method A Suitable for natural, NAc and NNMe<sub>2</sub> derivatives. A mixture of 1:2 acetic anhydride and pyridine (1 mg/mL of lyso GSL) was added to a dried sample of natural GSL, GSL S or GSL SNNMe<sub>2</sub> and stirred at 37° C. The reactions were monitored every 30 minutes by TLC using DCE:is<sup>o</sup>PrOH; 80:15 as solvent system, and upon completion, dried under a stream of N<sub>2</sub>.

Method B Suitable for the preparation of NTca(OAc)<sub>n</sub> and NTfa(OAc)<sub>n</sub> derivatives. A mixture of 2:1 trifluoroacetic anhydride and glacial acetic acid (1 mL/mg of glycolipid) was added to a dried sample of NTfa or NTca, GSL derivatives and stirred at 25° C. The reactions were monitored every 30 minutes by TLC using DCE:is<sup>o</sup>PrOH; 80:15 as solvent system, and upon completion, dried under a stream of N<sub>2</sub>.

The peracetylated crude was dissolved in DCE (1 mL) and loaded on to a silica column (for 3 mg, 0.5 X 5 cm in DCE) and eluted DCM:MeOH; 25:Y, Y being methanol which was varied from 100 µL in increments of 100 µL, where for each case 6, 4 mL fractions were collected. It is noteworthy that the mobility of most of the peracetylated derivatives during column chromatography vary significantly with the degree of silica gel activation, and concomitant changes of the solvent ratio of the eluent may be necessary.

Synthesis of Adamantyl Glycoconjugates of Gb<sub>3</sub>C and LC

A mixture of 1:2 acetic anhydride and pyridine (1 mg/mL of GSL) was added to a dried sample of natural Gb<sub>3</sub> and LC and stirred at 37°C. The reactions were monitored every 30 minutes by TLC using DCE:is<sup>o</sup>PrOH, 80:15 as the solvent system, and upon completion, dried under a stream of N<sub>2</sub>. The peracetylated crude product was dissolved in DCE (1 mL) and loaded on to a silica column (for 3 mg, 0.5 X 5 cm in DCE) and eluted DCM:MeOH; 25: Y, Y being methanol which was varied from 100 µL

- 42 -

in increments of 100  $\mu\text{L}$ , where for each case 6, 4 mL fractions were collected. It is noteworthy that the mobility of most of the peracetylated derivatives during column chromatography vary significantly with the degree of silica gel activation, and concomitant changes of the solvent ratio of the eluent were necessary.

5           The oxidation and coupling of the oxidized of peracetylated derivative was carried out as described under the oxidation section.

          The adamantyl glycoconjugates of Gb<sub>3</sub>C and LC are shown in Figure 6.

Oxidation Reactions:

10

Oxidation Using  $\text{KMnO}_4/\text{tBuOH}/\text{H}_2\text{O}/\text{NaIO}_4/\text{K}_2\text{CO}_3$  System:

          Reagent: A 2:1 mixture of  $\text{tBuOH}:\text{H}_2\text{O}$ . Solutions of  $\text{NaIO}_4$  (0.4 M),  $\text{K}_2\text{CO}_3$  (0.25 M) and  $\text{KMnO}_4$  (0.05 M). Quenching solution: A 5:1 mixture of 0.24 M  
15  $\text{NaHSO}_3$  solution and 0.5 M  $\text{H}_2\text{SO}_4$  solution.

          Peracetylated glycolipid (0.5 mg; depending on the GSLs this might vary from 1 to 0.3  $\mu\text{mol}$ ) was dissolved in  $\text{tBuOH}/\text{H}_2\text{O}$  (500  $\mu\text{L}$ ) and solutions of  $\text{NaIO}_4$  (30  $\mu\text{L}$ , 10  $\mu\text{mol}$ ),  $\text{K}_2\text{CO}_3$  (10  $\mu\text{L}$ , 2.5  $\mu\text{mol}$ ) and  $\text{KMnO}_4$  (15  $\mu\text{L}$ , 0.75  $\mu\text{mol}$ ) were added in the given sequence. The resulting purple, turbid mixture was stirred at 37° C for 2 to  
20 3 hours, depending on the GSL. If purified peracetylated derivatives are employed, the overall color of the reaction mixture should not diminish during the course of the reaction. However, if diminishing purple color is observed (due to the presence of impurities) with concomitant formation of brown  $\text{MnO}_2$ , additional aliquots (5  $\mu\text{L}$ ) of  $\text{KMnO}_4$  solution should be added. The reaction was quenched by the addition of 1.5  
25 mL of quenching solution and 1 mL of water and the resulting colorless solution was extracted three times with 5 mL portions of  $\text{Et}_2\text{O}$ . If, during the ether extraction procedure, any yellow color is observed, the combined organic phase is extracted with 1 mL of quenching solution. The combined organic phase is washed twice with 1 mL portions of water and dried under  $\text{N}_2$  at 25° C. Residual water present in the crude  
30 product can be removed by adding 1 to 2 mL absolute  $\text{EtOH}$  and removing under  $\text{N}_2$ . The product was dissolved in 2:1  $\text{DCM}:\text{MeOH}$  and stored below -20° C.

          Deacyl GSLs (0.3 mg) were dissolved in  $\text{tBuOH}/\text{H}_2\text{O}$  (500  $\mu\text{L}$ ) and solutions of  $\text{NaIO}_4$  (30  $\mu\text{L}$ , 10  $\mu\text{mol}$ ),  $\text{K}_2\text{CO}_3$  (10  $\mu\text{L}$ , 2.5  $\mu\text{mol}$ ) and  $\text{KMnO}_4$  (15  $\mu\text{L}$ , 0.75  $\mu\text{mol}$ ) were added in the given sequence. The resulting purple, turbid mixture was  
35 stirred at 37° C for 1 to 2 hours, depending on the type of GSL•S. To isolate peracetylated serine oligosaccharide acids which have hydrophobic amino substituents

- 43 -

like benzoyl or Tfa, the workup procedure employed to isolate ceramidic acids is applicable. However, in the case of less hydrophobic substituent like acetyl or charged groups like NMe<sub>2</sub>, the reaction was quenched by the addition of an excess of solid NaHSO<sub>3</sub> (50 mg) or Na<sub>2</sub>SO<sub>3</sub> (2 to 4 mg), gives a colorless, or occasionally pale yellow, suspension. This suspension is then dried on a rotary evaporator and extracted with C:M:W' 80:20:2 (15 to 20 mL) which in turn was passed through a silica column (0.5 cm X 4 cm in the same solvent) to remove most of the salts.

In the case of more polar GSIs, such as sulphatides and gangliosides, oxidation was carried out in a more polar medium containing 1:1 tBuOH:H<sub>2</sub>O.

Deprotection of the ceramidic acids or the serine oligosaccharide acids were carried out by treating 0.5 mg of dry ceramidic acid with 1 mL of triethyl amine solution (Et<sub>3</sub>N:MeOH:H<sub>2</sub>O; 2:6:10) at 37° C for 2 to 3 hours. The reaction mixture was dried under N<sub>2</sub> and the residue redissolved in 2:1 DCM:MeOH.

Oxidation using KMnO<sub>4</sub>/tBuOH/H<sub>2</sub>O/NaIO<sub>4</sub> System:

For the oxidation of Gb<sub>4</sub> 4 mgs of peracetylated Gb<sub>4</sub> was dissolved in 4 mls of a 2:1 solution of chloroform and methanol. The sample was dried. 4 mls of a 2:1 solution of tBuOH and water, 240 µl 0.4 M NaIO<sub>4</sub> and 120 µl 0.05M KMnO<sub>4</sub> were added. The resulting solution was stirred at room temperature. The reaction was quenched with 1 ml of water and 1.5 mls of a quenching solution, consisting of 5:1 0.24M NaHSO<sub>3</sub>:0.5 N H<sub>2</sub>SO<sub>4</sub>. The quenching was complete when the purple color of the reaction mixture had turned colorless. The product was then extracted with 5 mls of ether three times. The organic phases were combined and washed once with 1 ml of water. The resulting organic layer was dried under nitrogen. The residue was then dissolved in 5 mls of 2:1 chloroform:methanol.

For the oxidation of Gg<sub>3</sub>, a similar procedure was followed. 3-4 mgs of Gg<sub>3</sub> was added to 5 mls of the 2:1 chloroform: MeOH. The remainder of the procedure of the oxidation was the same.

For both Gb<sub>4</sub> and Gg<sub>3</sub>, deprotection of the serine oligosaccharides was carried out by drying 5 mls of the products of the oxidation and then adding 200µl of water, 400 µl of methanol and 1.0 ml of triethylamine. The reaction mixture was then stirred at overnight at 37°C for Gb<sub>4</sub> and at the same temperature for three hours for Gg<sub>3</sub>. The samples were then dried and passed through a 2-cm silica column in a pasteur pipette with a glass wool plug and .5 cm suspension of celite in a 2:1 solution of chloroform:MeOH. The product was run through the column twice with a solvent of

- 44 -

80:20 chloroform:MeOH and was subsequently washed with 1.5 mls of 80:20:2 (chloroform:methanol:water). The product was then eluted with 6 mls of MeOH and dried. The residue was then dissolved in 1 ml of MeOH.

5                    *Glycolipid-Ampicillin Coupling Reaction*

Oxidized Gb<sub>4</sub> was coupled to ampicillin using the following procedure. 200µl of dry oxidized Gb<sub>4</sub> was added to three tubes with 20 mgs of Ampicillin and .5 mls of dry MeOH. In tube 1, 500 µl of a 5:1 solution of dioxane:triethylamine was also  
10 added. In tube 2, 500µl of a 5:1 solution of DMF:triethylamine was added. In tube 3, 500µl of a 5:1 solution of acetone:triethylamine was added. No difference in the products from the three reactions was found. 4 mgs each of HOBt (3-hydroxy-1,2,3,benzotriazin-4(3H)-one) and EDAC were added sequentially to each 5:1 solution. The solutions were then vortexed, sonicated, and stirred at 37°C overnight.

15                    The resulting products were then dried. 1 ml each of hexane and MeOH was then added to the sample and mixed. Then, an additional 6 mls of hexane was added and the upper layer was then removed. The product was then washed four times with 6 mls of MeOH. The upper layers were combined and dried. All three reaction products were then combined and dried. The product was then dissolved in 98:2  
20 chloroform:MeOH. A 2 cm column was done with an eluting solvent of 98:2 chloroform:MeOH, 90:15:1, (chloroform:MeOH:water), and methanol (1 column volume each). The MeOH fraction was then dried. The product was dissolved in 1 ml of 90:15:1 (chloroform:methanol:water) and another 2 cm column was done with an eluting solvent of 90:15:1 (chloroform:methanol:water) for one column volume. The  
25 product was then eluted with MeOH.

For the coupling of oxidized Gg<sub>3</sub>, the procedure was the same as above with the following changes. In tube 2, 500 µl of 5:1 Acetonitrile:triethylamine was used. After purification by column chromatography columns are done, the resultant products were dried. 1 ml of 98:2 chloroform:MeOH was added to the products and  
30 passed through a 1.5 cm column of Alumina N with a solvent of 98:2 chloroform:MeOH. The product was eluted with a solution of chloroform:methanol:water (90:15:1, 80:20:2, and 60:30:2) and dried.

35                    *Oxidation Using KMnO<sub>4</sub>/Crown Ether and KMnO<sub>4</sub>/Acetone Systems*

- 45 -

A slightly modified version of the procedure described by Young *et al.* (Young, J., W. W., Laine, R. A. and Hakomori, S. (1979) *J. Lipid Res.* 20, 275-278), was employed. Instead of forming the  $\text{KMnO}_4$ •crown-ether complex *in situ* by adding solid  $\text{KMnO}_4$  and crown-ether to a benzene solution of GSL precursor, the complex was  
 5 made separately and added to the reaction.

Reagent: To a solution of dicyclohexyl-18-crown-6 in benzene (0.05 M) an excess of  $\text{KMnO}_4$  (approx. 20 mg) was added and sonicated for 15 minutes. The mixture was then centrifuged and the purple supernatant was assumed to contain approximately 0.05 M solution of 1:1 adduct of  $\text{KMnO}_4$ •Crown-ether. This solution  
 10 should be freshly prepared since it slowly deposits  $\text{MnO}_2$  upon standing.

Oxidation of  $\text{Gal}(\text{OAc})_4\text{C}(\text{OAc})$  by  $\text{KMnO}_4$  in acetone was carried out according to the published procedure (MacDonald, D. L., L., P. and Hakomori, S. I. (1980) *J. Lipid Res.* 21, 642-645), except product purification was similar to the isolation of ceramidic acids described in the new method.  
 15

#### TLC analysis of Serine and Ceramide acids

TLC analysis of serine ( $\text{GSL}\cdot\text{S}^\bullet\text{COOH}$ ) and ceramide ( $\text{GSL}\cdot\text{C}^\bullet\text{COOH}$ ) acids is shown in Figure 7. The plates were run in 90:15:1  
 20 (Chloroform:Methanol:Water) and were run on the crude products of the oxidation reactions. The TLC analysis shows that the reactions run cleanly with a wide variety of substrates. Lanes 1-7 are a variety of simple glycosphingolipids, while lanes 8,9 and 14 are more complex glycosphingolipids. Lanes 11 and 15 contain charged glycosphingolipids.

The peracylated serine acids of natural ( $(\text{OAc})_4\text{GalC}\cdot\text{S}^\bullet\text{COOH}$ , lane 1), behenic ( $(\text{OAc})_4\text{Gal}^{\text{BC}}\cdot\text{S}^\bullet\text{COOH}$ , lane 2), and palmitic ( $(\text{OAc})_4\text{Gal}^{\text{PC}}\cdot\text{S}^\bullet\text{COOH}$ , lane 3) analogs of galactocerebroside and the peracylated ceramide acids of natural ( $(\text{OAc})_5\text{GalC}\cdot\text{C}^\bullet\text{COOH}$ , lane 4), behenic ( $(\text{OAc})_5\text{Gal}^{\text{BC}}\cdot\text{C}^\bullet\text{COOH}$ , lane 5), and palmitic ( $(\text{OAc})_5\text{Gal}^{\text{PC}}\cdot\text{C}^\bullet\text{COOH}$ , lane 6) analogs of galactocerebroside were compared to each  
 30 other. The mobilities of all the analogs were similar. Minor bands in lanes 2 and 3 corresponded to compounds in lanes 5 and 6, respectively. These minor bands represent compounds which were not oxidized fully to serine acids.

Similarly,  $(\text{OAc})_9\text{Gb}_3\cdot\text{S}^\bullet\text{COOH}$  (lane 8),  $(\text{OAc})_{10}\text{Gb}_3\cdot\text{C}^\bullet\text{COOH}$  (lane 9),  $(\text{OAc})_4\text{SGC}\cdot\text{C}^\bullet\text{COOH}$  (lane 11), deprotected  $\text{Gb}_5\cdot\text{C}^\bullet\text{COOH}$  (lane 14), and deprotected  
 35  $\text{GM}_1\cdot\text{C}^\bullet\text{COOH}$  (lane 15) are shown. The TLC also shows the ceramide and serine acids of deacyl GSLs:  $(\text{OAc})_4\text{Gal}\cdot\text{N}^{\text{t}}\text{Boc}^\bullet\text{S}^\bullet\text{COOH}$  (lane 17),  $(\text{OAc})_5\text{Gal}\cdot\text{N}^{\text{t}}\text{Boc}^\bullet\text{C}^\bullet\text{COOH}$  (lane

- 46 -

18), and  $\text{Gb}_3 \cdot \text{NAc}^{\text{C}}\text{COOH}$  (lane 20). Lanes 7, 10, 12, 13, 15 and 19 correspond to  $(\text{OAc})_5\text{GalC}$ , SGC (upper) and SGG (lower),  $(\text{OAc})_4\text{SGC}$ ,  $\text{Gb}_5$ ,  $\text{GM}_1$ , and lyso  $\text{Gb}_3$  ( $\text{Gb}_3 \cdot \text{S}$ ), respectively. Asterisks indicate intermediates formed during the reaction. The TLC plates show the relative purity of the products formed.

5

### Mass Spectroscopic Analyses

Permethylation of ceramidic acid,  $\text{Gg}_4 \cdot \text{C}^{\text{S}}\text{COOH}$  was performed according to published methods (Fan, J. Q., Huynh, L. H., Reinhold, B. B., Reinhold, V. N., Takegawa, K., Iwahara, S., Kondo, A., Kato, I. and Lee, Y. C. (1996) *Glycoconj. J.* 13, 643-648). To approximately 100  $\mu\text{g}$  of dried  $\text{Gg}_4 \cdot \text{C}^{\text{S}}\text{COOH}$ , a suspension of NaOH in DMSO (100  $\mu\text{L}$  of 5% suspension) was added and incubated at 25° C for 1 hour. To this 100  $\mu\text{L}$  of MeI was added and after allowing to stand at 25° C for 1 hour, unreacted MeI was removed by passing a stream of  $\text{N}_2$  for 15 minutes, 3 mL of water and 5 mL of DCM were added and the organic phase was washed three times with 3 mL portions of water and dried. The ES spectra were recorded on a SCIEX API III spectrometer and FAB on VG ZAB-SE using standard conditions (Aspinall, G. O., Monteiro, M. A., Pang, H., Walsh, E. J. and Moran, A. P. (1996) *Biochemistry* 35, 2489-2497).

Figure 8 shows the mass spectra of serine and ceramide acids of behenic analogues of GalC. For the serine acid derivative, (+) mode shows peaks at 612.6 and 634.6. These peaks represent the molecular weight of the behenic serine analogue of GalC (589) with one and two accompanying sodium atoms (612.6 and 634.6, respectively). The peak at 588.4 represents the molecular weight of the GalC-behenic serine acid analog without one hydrogen ion. GalC-behenic is represented by a single peak at 807.0. Similarly for the behenic ceramide analogue of GalC, shows peaks at 706.8, 684.8, 664.6, and 642.6 for the positive mode mass spectra. These peaks represent the compound plus two sodium ions and one acetyl group, the compound plus one sodium ion and one acetyl group, the compound plus two sodium ions and the compound plus one sodium ion, respectively. In negative mode, the peaks are at 660.8, 618.4 and 588.4. These peaks represent the compound plus an acetyl group and missing one hydrogen ion, the compound missing one hydrogen ion, and the serine acid analogue respectively. These mass spectra show that compounds identified as the serine and ceramide behenic analogues of GalC, have the expected molecular weights and, hence are likely to actually be the desired compounds.

35

In Figure 9, the mass spectra of serine and ceramide acids of palmitic analogue of GalC are shown. For the serine acid analogues, in the (+) mode there are

- 47 -

peaks at 528.4 and 550.4. The peaks at 528.5 and 550.4 are the compound plus one sodium ion and the compound plus two sodium ions, respectively. The minor peaks at 558.6 and 580.4, represent incompletely oxidized ceramide acid analogues. In negative mode, the major peak at 504.4 is the molecular weight of the compound with out one hydrogen ion. The GalC palmitic analogue is represented by a single at 722.6. For the ceramide acid of the palmitic analogue of GalC, peaks are found at 558.4 and 580.4 in (+) mode, representing the compound plus one and two sodium ions, respectively. In negative ion mode there is a single peak at 534.4 representing the mass of the compound with out one hydrogen ion. This data shows that the molecular weights of the serine and ceramide acids of palmitic analogues of GalC are as expected and the compounds synthesized are the ones that were desired.

The theoretical fragmentation patterns of the serine and ceramide acid compounds are shown in Figure 10. In Figure 11, the negative ion mass spectrum of the serine acid from GM<sub>1</sub> is shown. The major peak at 1350.8 represents the compound, GM<sub>1</sub>C•<sup>s</sup>COOH.

#### Galactosyl Ceramide/BSA Coupling Reaction and gp120 Binding

The precursors derived from Gal•C, Gal•C-<sup>s</sup>COOH, Gal•S-COOH and Gal•S of were coupled to BSA. Prior to coupling, the oxidized products, GAL(OAc)<sub>4</sub>C(OAc)-<sup>s</sup>COOH and GAL(OAc)<sub>4</sub>S(OAc)-COOH (500 µg) were deprotected with 1;1;0.2 Et<sub>3</sub>N/MeOH/H<sub>2</sub>O at 37°C for 16 hours. The reaction mixture was dried. The crude deprotected acids, Gal•C-<sup>s</sup>COOH and Gal•S-COOH were dissolved (0.5 mL of C:M:W; 90:10:1) and loaded on to a silica column (0.5 X 2 cm) and eluted, first with C:M:W; 80:20:2 (5 mL) and then with MeOH (6 mL). The Gal•C-<sup>s</sup>COOH and Gal•S-COOH precursors were converted to the corresponding NHS derivatives by treating (dissolved in 5:1 AcCN:Et<sub>3</sub>N to give a final concentration of 1 mg/mL) with PNHS (Giambattista, M. D., Nyssen, E., Pecher, A. and Cocito, C. (1999) *J. Biol. Chem.* 29, 9203-9211; Ogura, H., Nagai, S. and Takeda, K. (1980) *Tetrahedron Lett.* 21, 1467-1468) or OxNHS (Kometani, T., Fitz, T. and Watt, D. S. (1986) *Tetrahedron Lett.* 27, 919-922) (2 to 4 equivalence) at 37° C for 3 hours. Then the solvent was removed under a flow of N<sub>2</sub> and a solution of BSA in PBS (2 mg/mL stock, 1:1 w/w ratio of BSA:acid) was added and stirred at 37° C for 24 hours. Psychosine (Gal•S) was coupled by adding a solution of BSA (2 mg/mL in PBS) in 1:1 ratio (w/w) and the resulting mixture was treated with the coupling reagent (2 to 4 equivalence) and stirred at 37° C for 24 hours. The reaction mixture was transferred into a centricon-30

- 48 -

and washed 3 times with 1mL portions of PBS. These BSA conjugates were separated by SDS-PAGE, transferred to nitrocellulose or adsorbed directly on to nitrocellulose and tested for recombinant gp120 (gp120) binding.

The nitrocellulose membranes were blocked with 5% milk powder, 0.05% tween-20 in 10mM TBS for 2 hours. Rinsed 3 times (10 to 15 minutes each) with 0.05% tween-20 in 10 mM TBS and incubated with rgp120, 1:1000 dilution in 3% milk powder in 10 mM TBS for 2 hours. Washed as described above and incubated with human HIV serum, 1:50 dilution in 5% milk powder, 0.05% tween-20 in 10 mM TBS for 2 hours. After rinsing as described above, the blots were incubated with the secondary antibody (anti-human IgG horse radish peroxidase conjugate), 1:1000 dilution in 5% milk powder, 0.05% tween-20 in 10 mM TBS for 45 minutes. Finally the blots were rinsed 3 times with 0.05% tween-20 in 10 mM TBS and a fourth rinse with only 10 mM TBS. Binding was visualized according to previously published procedure (Lingwood, C. A., Law, H., Richardson, S., Petric, M., Brunton, J. L., DeGrandis, S. and Karmali, M. (1987) *J. Biol. Chem.* 262, 8834-8839), by treating with 4-chloro-1-naphthol (3 mg/mL freshly prepared solution in methanol mixed with 5 volumes of 10 mM TBS and 1:1000 dilution of H<sub>2</sub>O<sub>2</sub>). The assays for BSA conjugates were all of the Western type. In the case of Gal•C conjugates, human sera from HIV patients were used to detect the bound gp120.

Analysis of approximately 5 µg of each conjugate by "western" or by dot blot gp120 overlay, showed that the conjugates (GalC•SCOHN)<sub>n</sub>BSA and (GalC•SNHOC)<sub>n</sub>BSA showed similar binding to gp120, whereas no binding was observed for (GalS•NACCOHN)<sub>n</sub>BSA conjugate. In (GalC•SCOHN)<sub>n</sub>BSA and (GalC•SNHOC)<sub>n</sub>BSA conjugates the respective binding moieties retain an hydrocarbon chain - the sphingosine base or the fatty acyl chain, respectively. Thus, even if the galactose residue is presented in a multivalent form, the galactosyl serine oligosaccharide conjugate (GalS•NACCOHN)<sub>n</sub>BSA, is not recognized by gp120, indicating the presence of at least one of the hydrocarbon chains is essential for binding. This is consistent with the lack of binding inhibition by free galactose (Bhat, S., Spitalnik, S. L., Gonzalez-Scarano, F. and Silberberg, D. H. (1991) *Proc. Natl. Acad. Sci. USA* 88, 7131-7134). Influenza A virus also binds to galactosyl ceramide or sulfatide (Suzuki, T., Sometani, A., Yamazaki, Y., Horiki, G., Mitzutani, Y., Masuda, H., Yamada, M., Tahara, H., Xu, G., Miyamoto, D., Oku, N., Okada, S., Kisio, M., Hasagawa, A., Ito, T., Kawaoka, Y. and Suzuki, Y. (1996) *Biochem. J.* 318, 389-393), and again the lipid moiety is important for binding. The BSA conjugate may therefore also bind this virus.



- 49 -

The Western blot analysis method was also used for the GalC•BSA conjugates analyzed in Figure 12a. A western blot analysis of GalC-glycoconjugates (3 to 4 mg each) binding to recombinant gp120 was done. Lane A was BSA. Lanes B, C, and H were GalC•<sup>c</sup>CONH)nBSA. Lanes D and E were (GalS•NHOC)nBSA. Lanes F and G were (GalBehenicC•<sup>c</sup>CONH)nBSA. The conjugates in lanes A, D, and F were derived using di(N-succinimydyl)oxalate. The conjugates in lanes C, E, and G were derived using succinimidyl phosphate, while the conjugate in lane H was derived using EDAC and NHS. In all cases a ratio of 1:1 w/w of BSA:Gb<sub>3</sub>C•CCOOH was used. This Western blot shows binding to Gb<sub>3</sub> occurs for all the compounds tested. The upper bands indicate other degrees of binding. BSA can bind Gb<sub>3</sub> in a variety of ways and the smaller bands are indicative of minor forms of binding.

A slot blot analysis was done on lanes B, C, D, and H (Figure 12b). The slot blot shows dose response for different GalC conjugates. The highest concentrations correspond to 2 to 3 mg.

Figures 12c and d are dot blot analyses showing dose response for (Gb<sub>3</sub>C•CCONH)nBSA conjugates. The highest concentrations corresponds to 1 to 2 mg. Figure 12c corresponds to a dot blot with conjugates derived using di(N-succinimydyl)oxalate and Figure 12d corresponds to conjugates derived from using EDAC and NHS. These figures show that the conjugates derived from using EDAC and NHS are several times more active than those derived from using di(N-succinimydyl)oxalate.

#### Gp120 Inhibition Assay

Stock solutions (1 mg/ml) of inhibitors were made up in ethanol. Appropriate amounts (i.e., such that at the end of all the manipulations the inhibitor concentrations will be either 100 µM or 10 µM) from these stock solutions were transferred into polypropylene tubes and solvent removed under a flow of N<sub>2</sub>. The dried samples were dissolved in 900 µL of 50 mM TBS by sonication and vortexing. To each tube was added 50 µL of 0.2% BSA in TBS and 50 µL of 0.2% gelatin and vortexed well and incubated at room temperature for 2 hours. To these solutions was added 5 µL gp120 (1 µg/5 µL in PBS) stock solution and vortexed (1 min) and shaken at room temperature for 2 hours.

Five to seven micrograms of SGC or GalC was spotted onto a aluminum backed nanosil silica plate and blocked with 1% gelatin in 50 mM TBS for 45 minutes at 37°C. After washing (3 times with 5 mL of 50 mM TBS) gp 120 that was preincubated with the inhibitor was added to the TLC plates and incubated for 2 hours at room

- 50 -

temperature. Gp 120 was washed (3 times with 5mL of 50 mM TBS) and the plates were incubated with sera from human HIV patients (1:50; human sera: 50 mM TBS containing 1% gelatin for 2 hours at room temperature and washed as above. The plates were incubated with goat anti-human IgG horse radish peroxidase conjugate (1:1000; GAH:50mM TBS containing 1% gelatin) for 45 minutes and washed as above; developed with 4-chloro-1-naphthol (3 mg/mL freshly prepared solution in methanol mixed) with 5 volumes of 50 mM TBS and 1:1000 dilution of H<sub>2</sub>O<sub>2</sub>.

Figure 13 shows inhibition of HIV coat protein gp120 binding to Galactocerebroside (GalC) and Sulfatide (SGC). The results are also summarized in Table 2 below. Table 2 shows that unoxidized compounds are more efficient inhibitors of GalC and that none of the compounds were noticeably effective against GalC under the given conditions.

Table 2

Compound #	At 100 M Inhibitor Concentration % Inhibition		At 10M Inhibitor Concentration % Inhibition	
	SCG	GalC	SGC	GalC
1	100%	N/C	>50%	N/C
2	100%	N/C	>50%	N/C
3	50%	N/C	N/I	N/C
4	N/I	N/C	N/I	N/C
5	N/I	N/C	N/I	N/C
6	>30%	N/C	N/I	N/C
7	>30%	N/C	N/I	N/C

Inhibition is estimated by comparing the intensity of gp120 binding for each inhibition assay and the control. The control has 0% inhibition. Assay for all the compounds were done at the same time.

N/C: Not conclusive

N/I: No inhibition

#### Lipid Receptor Binding Specificity of Verotoxin Producing E. coli

Studies have established that verotoxin producing E. coli (six strains tested) specifically bind to Gg4 and PE. Sulfatide is also bound. Comparison of this binding specificity with enteropathogenic E. coli (six strains tested) demonstrated that receptor activity of these lipids for this class of E. coli is considerably less than for

- 51 -

VTEC strains (Figure 14). In comparison, binding of commensal and non-pathogenic laboratory *E. coli* strains to these lipid structures *in vitro* appears to correlate with bacterial pathogenicity.

5 *E. coli* adherence is defined by a two stage process; firstly as a loose attachment to host cells, and secondly, a more consolidated tight attachment involving the intimin protein. In EPEC this initial loose attachment is mediated by the bundle forming pilus. However, in VTEC the mechanism of such initial host cell interaction is unknown. It is believed that the selective binding of Gg4 and PE by VTEC may function in place of the bfp-mediated attachment.

10

#### Antibiotic/glycolipid conjugates

Dimethyl deacyl Gg3 was coupled to N-acetyl penicillin (as indicated for Gg4 in Figure 1B) and tested the efficacy of the conjugate ('receptocide') on the growth  
15 of *Hemophilus influenzae* (which has been shown to bind Gg3 *in vitro*). N-acetyl penicillin is considered a poor antibiotic for *Hemophilus influenzae* and was found by agar gel diffusion to be virtually ineffective against this organism under the conditions used. However the "receptocide" was found to be almost as effective to inhibit *H. influenzae* as penicillin. Thus targeting the antibiotic by coupling to Gg3 had a major  
20 effect (several orders of magnitude) to increase antimicrobial efficacy.

In a second study, globotetraosyl ceramide (Gb4) was coupled to ampicillin via oxidation of the glycolipid as shown in Figure 3 for Gg3. Uropathogenic  
25 *E. coli* express P pili to mediate binding to globoseries glycolipids. In Figure 15 it can be seen that the Gb4-ampicillin conjugate was effective to inhibit the growth of an uropathogenic *E. coli* (more than ampicillin itself) but was not effective for a VTEC strain (which does not bind Gb4). It was observed that the VTEC was less sensitive to Gb4-ampicillin than to ampicillin, suggesting that such receptocides may be even more specific than expected. The uncoupled glycolipid demonstrated no inhibitory effect.

30 These results demonstrate the validity of this approach to treat SLTs and generate targeted antibiotics, such as receptocides which show enhanced antibacteriocidal activity according to bacterial binding specificity.

#### Inhibition of VT1 binding to Gb3 Phospholipid Bilayer

35 It has been shown that the binding of verotoxin to synthetic galabiose glycolipid species was markedly dependent on the nature of the lipid moiety (Boyd, B.

*et al.* "Lipid Modulation of Glycolipid Receptor Function: Presentation of Galactose  $\alpha$ 1-4 galactose Disaccharide for Verotoxin Binding in Natural and Synthetic Glycolipids" Eur. J. Biochem. 223: 873-878 (1994) and Pellizzari, A. *et al.* "Binding of Verocytotoxin 1 to Its Receptor is Influenced by Differences in Receptor Fatty Acid Content" Biochem. 31:1363-1370 (1992)). Moreover, binding of verotoxin to human renal Gb<sub>3</sub> was found to be a function of the fatty acid heterogeneity within the ceramide moiety (Pellizzari, A. *et al.* "Binding of Verocytotoxin 1 to Its Receptor is Influenced by Differences in Receptor Fatty Acid Content" Biochem. 31:1363-1370 (1992) and Kiarash, A. *et al.* J. Biol. Chem. 269:11138-11146 (1994)). It has also been shown that binding of two members of the verotoxin family (VT1 and VT2c), which show a thousand-fold difference in cytotoxicity *in vitro* dependent on B subunit/receptor binding, preferentially bound different fatty acid-Gb<sub>3</sub> isoforms. An interesting observation was made at this time in that these two toxins did not compete together for glycolipid binding when binding the preferred fatty acid isoform. This problem was resolved in part in by molecular modeling studies in which it was proposed there were in fact two Gb<sub>3</sub> binding sites per B subunit monomer. It was therefore suggested that the different toxins preferentially used these different receptor binding sites and that different Gb<sub>3</sub> conformations could be preferentially accommodated in two different sites and such conformations were defined by the lipid content of the globotriaosyl ceramide. First it is believed that not only does the presence of the glycolipid result in a million-fold increase in binding affinity but that the lipid moiety in some way influences the relative conformation of the carbohydrate to fit either one or the other binding site on the toxin. It is this effect of the lipid moiety on the conformation of the oligosaccharide that is successfully mimicked by the present invention. The concept includes that the molecule contains a truncated glycolipid (glycolipid acid) in which both the fatty acid has been removed and the sphingosine double bond cleaved (i.e., combination of i and ii above), with a rigid hydrophobic group which can mimic the effect of the lipid moiety of sugar conformation without allowing the lateral lipid packing that results in the formation of lamellar and micellar glycolipid structures in aqueous buffers.

Two such soluble Gb<sub>3</sub> analogs were produced using the oxidative hydrolysis procedure described above: an adamantyl and an acridine conjugate to the glycolipid acid. The adducts were filtered prior to use to ensure solubility. Unlike the free globotriaose, these species are potent inhibitors of <sup>125</sup>I-VT1 binding to immobilized Gb<sub>3</sub> presented in a phospholipid matrix (Figure 16) (VT1 B subunit was used as positive control). These results demonstrate that these soluble membrane Gb<sub>3</sub> mimics are effective in preventing toxin binding to Gb<sub>3</sub> in a phospholipid bilayer within

- 53 -

the micromolar range. This is the first description of any effective soluble competitive inhibitor of verotoxin receptor glycolipid binding. In this assay, the free globotriaose is totally ineffective.

The study shows that binding of bacterial pathogens to Gg<sub>3</sub> or Gg<sub>4</sub> is not  
5   inhibitable by the free galNAc1-4gal disaccharide. This is thus analogous to the  
VT1/Gb<sub>3</sub> binding. In the case of the 'receptocides' described above, the antibiotic  
moiety has served to mimic the effect of the lipid component on the oligosaccharide  
receptor function. The generation of receptocides from soluble Gg<sub>3</sub> mimics, instead of  
Gg<sub>3</sub> itself, can also be achieved by combination of derivatizations e.g. where R =  $\alpha$ -  
10   adamantane in Figure 3.

#### Binding assay for VT

All assays were done in triplicates and the wells of the edges of the plates  
15   (from Evergreen scientific, untreated 96-well, flat bottom, polystyrene, clear plates)  
were not included. To each well added (50  $\mu$ L) stock solutions of various  
concentrations (0.5  $\mu$ g/mL 0.4  $\mu$ g/mL etc.) of lipids (pure adamantyl glycoconjugate or  
Gb<sub>3</sub>C or LC in EtOH) and dried overnight. The wells were blocked with 200  $\mu$ L of  
20   blocking solution (0.2% BSA in PBS) for 2 hours at 37°C and washed (3 times with 200  
 $\mu$ L of 0.2% BSA in PBS, each for 3 minutes). The wells were incubated for two hours  
at room temperature with varying amounts of VT1 (10 to 50  $\mu$ g in 0.2% BSA in PBS)  
where the final incubation volume in each well was constant (60  $\mu$ L) and washed as  
described above. The samples were then incubated with PH1 (60  $\mu$ L, 1mg/mL in 0.2%  
25   BSA in PBS) for 1 hour at room temperature, washed as described above, incubated  
with GAM (sigma, 1:2000 dilution in 0.2% BSA in PBS) for 1 hour at room  
temperature, washed as described above, and then washed with PBS. The samples were  
then developed with 100  $\mu$ L of substrate solution (0.5 mg/mL of ABTS (2,2'-azino-  
bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt) in citrate buffer (0.08 M  
citric acid and 0.1 M NaH<sub>2</sub>PO<sub>4</sub>) and recorded after 10 to 15 minutes at 415 nm.

30   The results from the assay are shown in Figure 17. The typical binding  
assay with VT1 shows that the adamantine derivative from ceramide acid has a very  
high affinity and that the derivative has an affinity between that of natural Gb<sub>3</sub> and  
ceramide-adamantine derivatives. LC derivatives showed no binding under these  
conditions. This suggested that the Gb<sub>3</sub> compounds have a very high degree of  
35   specificity. The TLC overlay showed similar results with LC ceramide acids.

- 54 -

The TLC overlay of adamantyl conjugates of Gb<sub>3</sub> LC and GalC is shown in Figure 18. The TLC plate shows the relative migration of adamantyl glyconjugates of Gb<sub>3</sub>C, LC and GalC and natural GSLs. Lane A shows three bands: GalC, Gb<sub>3</sub> and Gb<sub>4</sub>C (1 µg each). Lane B shows the same compounds (2 µg each). Lane C is Gb<sub>3</sub>C•<sup>s</sup>CONHAda. Lane D is Gb<sub>3</sub>C•<sup>c</sup>CONHAda. Lane E is LC•<sup>s</sup>CONHAda. Lane F is LC•<sup>c</sup>CONHAda. Lane G is GalC•<sup>s</sup>CONHAda and Lane H is GalC•<sup>c</sup>CONHAda. The plate was developed with orcinol spray. A second TLC plate was run having the same amount of lipids and run under identical conditions. It was analyzed by using TLC overlay with verotoxin. In this assay, single bands in Lanes A, B, C, and D are visible corresponding to the mobility of Gb<sub>3</sub>. This assay shows that verotoxin binds to Gb<sub>3</sub> but not the other compounds present in these lanes. In Lane F, verotoxin is shown to bind to LC•<sup>c</sup>CONHAda.

#### Inhibition Assay for VT binding

The procedure above for the VT binding assay was used with the following modifications. All wells were coated with 60 ng of Gb<sub>3</sub>.

Verotoxin was preincubated with the inhibitor for 2 hours and this mixture was then added to the Gb<sub>3</sub> coated wells. For example: from a 25mM stock (in EtOH) of inhibitor, 22 µL was transferred into a glass tube, dried added 220 µL of PBS (2.5 mM of inhibitor) and from this solution a serial 2 fold dilutions were carried out with PBS where the final 110 µL aliquot was discarded. To each dilution added 100 µL of VT solution (160 ng/mL in PBS) and incubated for 2 hours at room temperature. Then 60 µL aliquots were transferred into wells (3 wells) containing Gb<sub>3</sub> and incubated for 2 hours at room temperature.

Figure 19 shows the inhibition by N-adamantylacetyl Gb<sub>3</sub> derivatives using the above mentioned assay. PH1 is a natural monoclonal antibody against VT1. The results of the assays shows that Gb<sub>3</sub>S•NHCOCH<sub>2</sub>Ada (A) was the most efficient inhibitor against VT1 binding. At concentrations around 10<sup>-2</sup> mM of inhibitor, almost none of the VT1 is bound. The hydrophobic tail is believed to be important to the binding. It was noted that without the tail, the inhibition was reduced. Figure 20 shows that Gb<sub>3</sub>S•NHCOCH<sub>2</sub>Ada and Gb<sub>3</sub>S•NHAc<sup>c</sup>CONHAda are both apparently successful inhibitors of VT1 binding at concentrations 10<sup>-4</sup> mM of inhibitor. Gb<sub>3</sub>S•NH<sub>2</sub><sup>c</sup>CONHAda was not found to block the binding of VT1.

#### *Synthesis of SGC derivatives*

- 55 -

Sulfogalactosylceramide (SGC) derivatives were prepared by the following method. SGC were first hydrolyzed under basic conditions using 1M NaOH in MeOH at 102°C for 3-4 hours. The resulting amine was then coupled to the carboxylic acid of a rigid hydrophobic moiety using 1,2,3-benzotriazin-4(3-hydroxy)-one and EDAC in a 5:1 solution of methanol:triethylamine at 37°C for eighteen hours. The resulting compound was a SGC derivative. To protect the SGC-derivative, the compound was then dissolved in a 2:1 solution of pyridine:acetic anhydride at 37°C overnight. The resulting protected compound was then oxidized using a 2:1 solution of tBuOH:water and NaIO<sub>4</sub> and KMnO<sub>4</sub> at 37°C for sixteen hours. The resulting compound was then deprotected using triethylamine, water, and methanol at 37°C for sixteen hours.

#### *Assay for Hemagglutinin Activity*

When hemagglutinin (HA) is mixed with RBC they cause hemagglutination, a process by which the RBC's are linked together in a mesh-like network. Hemagglutination can be visualized in v-shaped wells, where agglutinated RBC settle out of suspension to form a diffused red layer at the bottom of the well ("button"). The RBC is not the type of host cell which the virus normally infects, but expresses on its surface NeuAc containing receptors similar to those found on mucous cells of the respiratory tract.

Figure 21 shows an assay for the determination of 1HA unit. To determine 1 HA unit, the following procedure was used. To a two fold dilutions of viral antigens in PBS (50 µL) in a V-shaped 96-well plate, 50 µL of PBS and 150 µL of RBC (0.5% in PBS,  $6 \times 10^7$  cells) were added and the reaction mixture was then incubated for 1 hour at 4 °C. The lowest antigen concentration that gave a positive hemagglutination was taken 1HA unit and the next highest as 2HA and so on. The HA used was A/Johannesburg/82/96/NIB-39 (HINI). Inhibition was carried out using 8 HAU and  $10^7$  RBC. A positive control of the assay was done using V-shaped wells charged with the following reactants 150 µl of 0.5% RBC ( $6 \times 10^7$  cells) in PBS, 50 µl of viral antigen in PBS, and 50 µl of PBS. The reaction was then incubated at 4°C for one hour. This resulted in no inhibition and, hence, no button. A negative control for hemagglutination was done without viral antigen. To test for inhibition SGC liposomes were used in the following procedure. 150 µl of 0.5% RBC ( $6 \times 10^7$  cells) in PBS, 50 µl of viral antigen in PBS, and 50 µl of soluble SGC inhibitor dissolved in PBS. It was then incubated for an hour at 4°C and

- 56 -

observed for the formation of a button. Each well contained RBC-SGC-liposomes at varying concentrations. Hemagglutinin was inhibited at 12.5 mM indicating that the viral antigen was neutralized by SGC-liposomes (Figure 22). This was confirmed by the viral antigen binding to SGC. Inhibition was carried out using 8 HAU and 10<sup>6</sup> RBC

5 Liposome ratio was 1:6:3 - SGC:PC:Chol. It was determined that to completely inhibit 1 HAU, 1.56 mM of SGC-liposomes are necessary.

*Determination of the Concentration at which SGC-derivatives do not lyse RBC*

10 In an attempt to prevent lysis, water soluble derivatives of SGC were synthesized, SGC-adamantane-3-acetic acid and oxidized SGC-adamantane. SGC-adamantane-3-acetic acid was synthesized because it has a negative charge on the hydrocarbon "cage" while in solution. Introduction of this extra negative charge made it more soluble and less likely to disrupt the RBC membrane. Oxidized SGC-adamantane

15 was synthesized to determine if the removal of the hydrocarbon "tail" would abolish the lysing effect.

For the determination of the concentration at which SGC derivatives do not lyse RBC, each well contained RBC and soluble SGC derivatives in varying concentrations (Figure 23). The wells to the left of the button showed lysis of RBC, an

20 *in vitro* effect. The hemagglutination inhibition assays were carried out at inhibitor concentrations which would not lyse the RBC. SGC-adamantane, SGC-norbornane and SGC-adamantane-3-acetic acid were found to lyse RBC at concentrations above 0.75  $\mu$  M, 1.5  $\mu$  M and 1.5  $\mu$  M respectively. Oxidized SGC-adamantane has no lysing effect on the RBC, because the hydrophobic "tail" of GC derivatives was crucial to lyse the RBC

25 (Figure 23).

*Preparation of SGC liposomes*

SGC liposomes were prepared according to the published procedure (Arab, S. and Lingwood, C.A. Glycoconj. J. 13:159-166 (1996). Multilamellar vesicles

30 containing PC/Chol/SGCs were used in order to avoid the high surface curvature of small unilamellar liposomes and the possible exclusion of the GSL during preparation of the large unilamellar liposomes by extrusion or solvent injection of the lipid mixtures. A chloroform:methanol (2:1 v/v) solution of the lipid mixtures in weight ratio of 1:5:2.5 of SGC:PC:Chol (as used in the microtitre plate binding assay) were added to a screw

35 capped glass tube and after evaporation of the solvent under a stream of nitrogen, was further dried under a vacuum for 1 hour. Then the lipids were dispersed in 60 mM Tris



- 57 -

buffered saline (TBS) pH 7.4 at a concentration of 10 ng/ $\mu$ l SGC by vortexing. The suspension was dispersed by alternate vigorous vortexing and heating for 30s at 90-95°C (5-10 °C above the lipid transition temperature) for a period of 10 minutes. Background binding to control liposomes lacking SGC, routinely >6% was subtracted.

5 Measurements were made in triplicate.

#### *Assay for activity of SGC derivatives*

SGC-adamantane was found to inhibit 1 hemagglutination unit (HAU) at a  
10 concentration of 1.3  $\mu$ M (see Figure 24). Each V-shaped well contained RBC.SGC0  
adamantane at varying concentrations and viral antigen. At 10  $\mu$ M and 5  $\mu$ M of the  
inhibitor, RBC lysis was observed. At 2.5  $\mu$ M and 1.3  $\mu$ M hemagglutination inhibition  
was observed. Inhibition was carried out with 1 HAU and a  $6 \times 10^4$  RBC.

SGC-norbornane and SGC-adamantane-3-acetic acid were found to  
15 inhibit 2 HAU at concentrations of 1.5  $\mu$ M and 0.75  $\mu$ M respectively (see Figure 24).  
Each V-shaped well contained a RBC.SGC derivative at varying concentrations and a  
viral antigen. SGC-norbornane was found to inhibit hemagglutination at 1.5  $\mu$ M and  
0.75 $\mu$ M. Non-sulfated GC-norbornane was ineffective in inhibiting hemagglutination,  
as was the case with the oxidized SGC-adamantane derivative. Inhibition was carried  
20 out with 2 HAU and  $6 \times 10^4$  RBC.

The results showed that 0.75  $\mu$ M of SGC-norbornane and 0.38  $\mu$ M of  
SGC-adamantane-3-acetic acid were needed to inhibit 1HAU. It was found that SGC-  
adamantane-3-acetic acid was a better inhibitor than SGC-norbornane, followed by  
SGC-adamantane.

25 A non-sulfated GC-norbornane was also tested. No hemagglutination  
inhibition was found to occur under the given conditions (Figure 16). This confirmed  
that hemagglutinin binds to the sulfated galactose domain of SGC.

Oxidized-SGC-adamantane did not inhibit hemagglutination even at  
concentrations as high as 50 $\mu$ M. It was inferred that the hydrocarbon "tail" ensures the  
30 proper presentation of the sugar, to bind to hemagglutinin.

Using TLC analysis, it was confirmed that the water soluble SGC mimics  
have similar properties to SGC based on TLC mobility. All the SGC-derivatives had  
almost the same mobility as SGC, except for oxidized-SGC-adamantane (Figure 25).

The results of the assays for SGC derivatives activities are shown below  
35 in Table 3. SGC-adamantane-3-acetic acid was found to be the best inhibitor of HAU  
activity.

**Table III: Inhibition activity of SGC Derivatives**

<b>SGC Derivatives</b>	<b>Inhibition of 1 HAU</b>
SGC-liposomes	1.6 mM
SGC-adamantane	1.3 $\mu$ M
Oxidized SGC-adamantane	<i>No Inhibition</i>
SGC-adamantane-3-acetic acid	0.38 $\mu$ M
SGC-norbornane	0.75 $\mu$ M
GC-norbornane	<i>No Inhibition</i>

**5 EQUIVALENTS**

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to specific embodiments of the invention described specifically herein. Such equivalents are intended to be  
10 encompassed in the scope of the following claims.

- 59 -

## CLAIMS

What is claimed is:

- 5 1. A method for treating a glycolipid mediated state in a subject comprising administering to a subject a therapeutically effective amount of a therapeutic compound represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent, such that the glycolipid mediated state is treated.
- 10 2. The method of claim 1, wherein said glycomimetic receptor moiety includes an oligosaccharide moiety coupled to a ceramide lipid base.
3. The method of claim 1, wherein said glycomimetic receptor moiety is gangliotriaosyl ceramide galNAc $\beta$ 1-4gal $\beta$ 1-4glc cer (Gg3) or gangliotetraosyl ceramide  
15 gal $\beta$ 1-4galNAc $\beta$ 1-4glc cer (Gg4) and derivatives thereof.
4. The method of claim 1, wherein said glycomimetic receptor moiety includes an oligosaccharide moiety coupled to a serine lipid base.
- 20 5. The method of claim 4, wherein said glycomimetic receptor moiety is glycosyl-N-acyl serine, globotriosyl-N-acyl serine, or galactosyl-N-acyl serine and derivatives thereof.
6. The method of claim 5, wherein said glycomimetic receptor moiety  
25 includes an oligosaccharide moiety coupled to a sphingosine lipid base.
7. The method of claims 1, wherein said oligosaccharide moiety has at least one sulfate substituent.
- 30 8. The method of claim 7, wherein said sulfated oligosaccharide is a sulfated galactose.
9. The method of claim 1, wherein said active agent is an antibiotic.
- 35 10. The method of claim 9, wherein said antibiotic is a penicillin, cepham or a cephalosporin.

- 60 -

11. The method of claim 1, wherein said active agent is a carbocyclic compound.
- 5 12. The method of claim 11, wherein said carbocyclic compound is selected from the group consisting of bicyclic, tricyclic and bridged compounds.
13. The method of claim 12, wherein said carbocyclic compound is an adamantyl, norbornyl or an acridine derivative.
- 10 14. The method of claim 13, wherein said adamantyl or norbornyl derivative is selected from the group consisting of adamantane, norbornane, adamantane-3-acetic acid, adamantane-1-acetic acid, adamantane-1,3-diacetic acid, and norbornane-3-acetic acid.
- 15 15. The method of claim 1, wherein said glycolipid mediated state is associated with a pathogenic microorganism.
16. The method of claim 15, wherein said pathogenic microorganism is a
- 20 bacteria.
17. The method of claim 16, wherein said bacteria is selected from the group consisting of *Streptococcus pneumoniae*, *Streptococcus agalactiae* (Gp. B.), *Branhamella catarrhalis*, *Chlamydia trachomatis*, *Chlamydia pneumoniae*, *Clostridium*
- 25 *perfringens*, *Clostridium difficile*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Borrelia burgdorferi*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Pseudomonas aeruginosa*, *Pseudomonas cepacia*, *Pseudomonas maltophilia*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Helicobacter pylori*, *Shigella dysenteriae*, *Shigella flexneri*, *Pasturella multocida*, *Coxiella burnetti*, *Mycobacterium tuberculosis*,
- 30 *Mycobacterium avium-intracellulare*, *Salmonella typhimurium*, *Escherichia coli* ATCC 6883, and *Escherichia coli* HB101/DH5a.
18. The method of claim 16, wherein said bacteria is VTEC.
- 35 19. The method of claim 1, wherein said pathogen is a virus.

20. The method of claim 19, wherein said pathogenic virus is selected from the group consisting of *Influenza A. B.* and *C.*
21. The method of claim 20, wherein said pathogenic virus is HIV.
- 5 22. A method of modulating interaction between a pathogen and a glycolipid in a subject comprising administering to a subject a therapeutically effective amount of a therapeutic compound represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent, such that interaction between a pathogen and a glycolipid is modulated.
- 10 23. The method of claim 22, wherein said glycomimetic receptor moiety includes an oligosaccharide moiety coupled to a serine lipid base.
- 15 24. The method of claim 23, wherein said glycomimetic receptor moiety is glycosyl-N-acyl serine, globotriosyl-N-acyl serine, or galactosyl-N-acyl serine and derivatives thereof.
25. The method of claim 22, wherein said glycomimetic receptor moiety includes an oligosaccharide moiety coupled to a ceramide lipid base.
- 20 26. The method of claim 25, wherein said glycomimetic receptor moiety is gangliotriaosyl ceramide galNAc $\beta$ 1-4gal $\beta$ 1-4glc cer (Gg<sub>3</sub>) or gangliotetraosyl ceramide gal $\beta$ 1-4galNAc $\beta$ 1-4glc cer (Gg<sub>4</sub>) and derivatives thereof.
- 25 27. The method of claim 22, wherein said glycomimetic receptor moiety includes an oligosaccharide moiety coupled to a sphingosine lipid base.
28. The method of claim 22, wherein said oligosaccharide moiety has at least one sulfate substituent.
- 30 29. The method of claim 28, wherein said sulfated oligosaccharide is a sulfated galactose.
- 35 30. The method of claim 22, wherein said active agent is an antibiotic.

- 62 -

31. The method of claim 30, wherein said antibiotic is a penicillin, cepham or a cephalosporin.
32. The method of claim 22, wherein said active agent is a carbocyclic  
5 compound.
33. The method of claim 32, wherein said carbocyclic compound is selected from the group consisting of: bicyclic, tricyclic and bridged compounds.
- 10 34. The method of claim 33, wherein said carbocyclic compound is an adamantyl, a norbornyl, or an acridine derivative.
35. The method of claim 34, wherein said adamantyl or norbornyl derivative is selected from the group consisting of adamantane, norbornane, adamantane-3-acetic  
15 acid, adamantane-1-acetic acid, adamantane-1,3-diacetic acid, and norbornane-3-acetic acid.
36. The method of claim 22, wherein said pathogen is a bacteria.
- 20 37. The method of claim 36, wherein said bacteria is selected from the group consisting of *Streptococcus pneumoniae*, *Streptococcus agalactiae* (Gp. B), *Branhamella catarrhalis*, *Chlamydia trachomatis*, *Chlamydia pneumoniae*, *Clostridium perfringens*, *Clostridium difficile*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Borrelia burgdorferi*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*,  
25 *Pseudomonas aeruginosa*, *Pseudomonas cepacia*, *Pseudomonas maltophilia*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Helicobacter pylori*, *Shigella dysenteriae*, *Shigella flexneri*, *Pasturella multocida*, *Coxiella burnetti*, *Mycobacterium tuberculosis*, *Mycobacterium avium-intracellulare*, *Salmonella typhimurium*, *Escherichia coli* ATCC 6883, and *Escherichia coli* HB101/DH5a.
- 30 38. The method of claim 36, wherein said bacteria is VTEC.
39. The method of claim 22, wherein said pathogen is a virus.
- 35 40. The method of claim 39, wherein said pathogenic virus is selected from the group consisting of *Influenza A*, *B*, and *C*.

- 63 -

- 41           The method of claim 39, wherein said pathogenic virus is HIV.
42.           A method treating a state characterized by the presence of a shiga-like  
5   toxin in a subject, comprising administering to a subject a therapeutically effective  
amount of a therapeutic compound represented by the structure A-B, in which A is a  
glycomimetic receptor moiety and B is an active agent, such that a state characterized by  
the presence of shiga-like toxin in the subject is treated.
- 10 43.           The method of claim 42, wherein said shiga-like toxin is a SLTI, a SLTII,  
a SLTIII or any cytotoxin similar in both structure and function to Shiga toxin.
44.           The method of claim 42, wherein said shiga-like toxin is verotoxin.
- 15 45.           A compound represented by the structure A-B, in which A is a  
glycomimetic receptor moiety and B is an active agent.
46.           The compound of claim 45, wherein said glycomimetic receptor moiety  
includes an oligosaccharide moiety coupled to a ceramide lipid base.
- 20 47.           The compound of claim 45, wherein said glycomimetic receptor moiety  
is gangliotriaosyl ceramide galNAc $\beta$ 1-4gal $\beta$ 1-4glc cer (Gg3) or gangliotetraosyl  
ceramide gal $\beta$ 1-4galNAc $\beta$ 1-4glc cer (Gg4) and derivatives thereof.
- 25 48.           The method of claim 45, wherein said glycomimetic receptor moiety  
includes an oligosaccharide moiety coupled to a serine lipid base.
49.           The compound of claim 48, wherein said glycomimetic receptor moiety  
is glycosyl-N-acyl serine, globotriosyl-N-acyl serine, or galactosyl-N-acyl serine and  
30 derivatives thereof.
50.           The method of claim 45, wherein said glycomimetic receptor moiety  
includes an oligosaccharide moiety coupled to a sphingosine lipid base.
- 35 51.           The method of claim 45, wherein said oligosaccharide moiety has at least  
one sulfate substituent.

- 64 -

52. The method of claim 51, wherein said sulfated oligosaccharide is a sulfated galactose.
- 5 53. The compound of claim 45, wherein said active agent is an antibiotic.
54. The compound of claim 53, wherein said antibiotic is a penicillin, cepham or a cephalosporin.
- 10 55. The compound of claim 45, wherein said active agent is a carbocyclic compound.
56. The compound of claim 55, wherein said carbocyclic compound is selected from the group consisting of: bicyclic, tricyclic and bridged compounds.
- 15 57. The compound of claim 55, wherein said carbocyclic compound is an adamantyl, a norbornyl or an acridine derivative.
58. The method of claim 57, wherein said adamantyl or norbornyl derivative is selected from the group consisting of adamantane, norbornane, adamantane-3-acetic acid, adamantane-1-acetic acid, adamantane-1,3-diacetic acid, and norbornane-3-acetic acid.
- 20 59. A pharmaceutical composition comprising a therapeutically effective amount of a therapeutic compound represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent and a pharmaceutically acceptable carrier.
60. The pharmaceutical composition of claim 59, wherein said active agent is an antibiotic.
- 30 61. A pharmaceutical composition for treating a glycolipid mediated state in a subject, comprising a therapeutically effective amount of a therapeutic compound represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent and a pharmaceutically acceptable carrier, such that a glycolipid mediated state is treated.
- 35




- 65 -

62. The pharmaceutical composition of claim 61, wherein said active agent is an antibiotic.
- 5 63. A pharmaceutical composition for modulating interaction between a pathogenic microorganism and a glycolipid in a subject comprising a therapeutically effective amount of a therapeutic compound represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent and a pharmaceutically acceptable carrier, such that interaction between a pathogenic microorganism and a  
10 glycolipid is modulated.
64. The pharmaceutical composition of claim 63, wherein said active agent is an antibiotic or a carbocyclic compound.
- 15 65. A packaged therapeutic composition for treating a glycolipid mediated state, comprising  
a container holding a therapeutically effective amount of a therapeutic compound for treating a glycolipid mediated state in a subject, said therapeutic compound represented by the structure A-B, in which A is a glycomimetic receptor  
20 moiety and B is an active agent; and  
instructions for using said therapeutic composition for treating the glycolipid mediated state.
- 25 66. A packaged therapeutic composition for modulating interaction between a pathogenic microorganism and a glycolipid, comprising  
a container holding a therapeutically effective amount of a therapeutic compound for modulating interaction between a pathogenic microorganism and a glycolipid in a subject, said therapeutic compound represented by the structure A-B, in which A is a glycomimetic receptor moiety and B is an active agent; and  
30 instructions for using said therapeutic composition for modulating interaction between the pathogenic microorganism and the glycolipid.
- 35 67. A method for the synthesis of serine oligosaccharides comprising oxidizing the sphingosine double bond of a glycosphingolipid under basic conditions,  
such that a serine oligosaccharide is synthesized.

68. The serine oligosaccharide produced by the method of Claim 67.

69. A serine oligosaccharide depicted below:

5



wherein R is selected from the group consisting of: an acyl group, hydrogen, phenyl ketone, methyl ketone, and t-butoxide ester; and where Q is a saccharide moiety.

10 70. An assay for determining gp120 binding activity, comprising:  
 exposing a gp120 binding compound to gp120 such that an  
 intermediate is formed;  
 removing unbound gp120 from said intermediate;  
 exposing said intermediate to HIV sera; and  
 15 detecting binding between gp120 of said intermediate and the  
 HIV sera.  
 thereby determining the gp120 binding activity of a gp120 binding  
 compound.

20 71. The assay of claim 70, wherein the said gp120 binding compound is first  
 coated on a TLC plate.

72. The assay of claim 70, wherein said gp120 binding compound includes  
 GalC.

25 73. The assay of claim 70, wherein said gp120 binding compound includes  
 an SGC.

74. The assay of claim 70, wherein said binding of gp120 to sera from an  
 30 HIV subject is detected by incubation with goat anti-human IgC horse radish peroxidase  
 conjugate.

75. The assay of claim 70, wherein said sera is from a human.


76. An assay for determining the inhibition between a Shiga-like toxin and a glycolipid receptor, comprising:

- 5                   providing a container coated with a glycolipid receptor;  
                  providing an inhibitor;  
                  exposing said glycolipid receptor to said inhibitor;  
                  providing a Shiga-like toxin; and  
                  analyzing ability of the Shiga-like toxin to bind to the glycolipid  
receptor,  
10                   thereby determining inhibition between a glycolipid receptor and a Shiga-  
like toxin.


77. The assay of claim 76, wherein said glycolipid receptor is Gb<sub>3</sub>.

15 78. The assay of claim 77, wherein said Shiga-like toxin is verotoxin.

1/27

**FIG. 1A**

2/27

**FIG. 1B**

3/27






FIG. 2A

4/27




**FIG. 2B**

5 / 27

*FIG. 3*




6 / 27

**FIG. 4**

SUBSTITUTE SHEET (RULE 26)

7/27

**FIG. 5**

8/27



Adamantyl glycoconjugates of Gb<sub>3</sub>C and LC

FIG. 6


9/27



*FIG. 7*

10/27

FIG. 8



11/27





FIG. 9

The diagram illustrates the chemical structures and reactions of various galactose derivatives. At the top, three galactose units are shown in their pyranose form, each with a sodium ion (Na<sup>+</sup>) and a hydroxyl group at C2. The central structure is labeled **203**. Arrows indicate the conversion of these galactose units into two different derivatives: **ceramide acid** (left) and **Serine acid** (right). The ceramide acid derivative is shown as a galactose unit linked to a fatty acid chain (CH<sub>2</sub>)<sub>n</sub> via an ester bond. The serine acid derivative is shown as a galactose unit linked to a serine residue (CH<sub>2</sub>CH(NH<sub>2</sub>)COOH) via an ether bond. The serine acid derivative is labeled **290**. The ceramide acid derivative is labeled **320**. Below these, the structures of the fatty acid chains are shown for different values of *n*: *n*=12, Gal<sup>P</sup>C<sup>S</sup>COOH, (M+Na) = 558; *n*=12, Gal<sup>P</sup>C<sup>S</sup>COOH, (M+Na) = 528; *n*=18, Gal<sup>B</sup>C<sup>S</sup>COOH, (M+Na) = 613. The serine acid derivative is also shown for *n*=12, Gal<sup>P</sup>C<sup>S</sup>COOH, (M+Na) = 528; *n*=18, Gal<sup>B</sup>C<sup>S</sup>COOH, (M+Na) = 613. The ceramide acid derivative is shown for *n*=12, 396; *n*=12, 366; *n*=18, 451. The serine acid derivative is shown for *n*=12, 366; *n*=18, 451. The structures are labeled with their respective molecular weights: 162, 203, 290, 320, 396, 451, 528, 558, 613. The structures are labeled with their respective molecular weights: 162, 203, 290, 320, 396, 451, 528, 558, 613.

*FIG. 10*


13/27

FIG. 11A





14/27

**FIG. 11B**

15/27







FIG. 12

16/27



*FIG. 13A*

17/27

**FIG. 13B**

SUBSTITUTE SHEET (RULE 26)

18/27






FIG. 14

19/27





*FIG. 15*

20/27

**FIG. 16**

21/27



**FIG. 17A****FIG. 17B**



22/27



*FIG. 18*

**FIG. 19**

24/27




INHIBITION BY  $Gb_3S\cdot NH_2^C CONHAda$  Vs  
 $Gb_3S\cdot NHAc^C CONHAda$ 




FIG. 20

25/27


Titration of viral antigen. Shown in duplicates

4 HA 2 HA 1 HA  
Unit Unit Unit*FIG. 21*

26 / 27

*FIG. 22**FIG. 23**FIG. 25*

27 / 27

**FIG. 24**

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 98/00817

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 A61K47/48 C07H15/26 C07H15/04 G01N33/569 C07H15/18		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K C07H G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	US 5 466 681 A (BLOMBERG A LENNART I ET AL) 14 November 1995 cited in the application  see the whole document	1-10, 15-31, 36-54, 59-66
Y	US 5 696 000 A (KRIVAN HOWARD C ET AL) 9 December 1997  see the whole document	1-10, 15-31, 36-54, 59-66
A	LINGWOOD C A: "AGLYCONE MODULATION OF GLYCOLIPID RECEPTOR FUNCTION" GLYCOCONJUGATE JOURNAL, vol. 13, no. 4, 1996, pages 495-503, XP002071690	1-10, 15-31, 36-54, 59-66
--- -/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified). "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "3" document member of the same patent family		
Date of the actual completion of the international search  28 January 1999		Date of mailing of the international search report  04. 06.99
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Bardili, W

# INTERNATIONAL SEARCH REPORT

		International Application No PCT/CA. 98/00817
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO 98 37915 A (LINGWOOD CLIFFORD A ;HSC RES DEV LP (CA)) 3 September 1998</p> <p>see the whole document -----</p>	<p>1-10, 15-31, 36-54, 59-66</p>



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 98/00817

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-10, 15-31, 36-54, 59-66

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/CA 98/00817

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1 -10,15-31,36-54,59-66

Conjugates of an antibiotic such as a penicillin and a glycomimetic receptor moiety; their use in medical treatment, in particular to combat infections by pathogens such as bacteria and viruses; pharmaceutical compositions containing the conjugates in any form including packages.

2. Claims: 11-14, 32-35, 42-44, 55-58, 59, 61, 63, 64-66

Conjugates of a carbocyclic compound such as adamantane and a glycomimetic receptor moiety; their use in medicine, in particular to combat infections involving verotoxin and shiga like toxins; pharmaceutical compositions containing the conjugates in any form including packages.

3. Claims: 67-69

Serine oligosaccharides and their synthesis.

4. Claims: 70-75

An assay for determining gp120 binding activity.

5. Claims: 76-78

An assay for determining the inhibition between shiga-like toxin and a glycolipid receptor.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/00817

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5466681 A	14-11-1995	NONE	
US 5696000 A	09-12-1997	AT 173827 T	15-12-1998
		CA 2095642 A	03-02-1992
		DE 69130536 D	07-01-1999
		DE 69130536 T	22-04-1999
		EP 0553113 A	04-08-1993
		ES 2127198 T	16-04-1999
		JP 6501383 T	17-02-1994
		WO 9202817 A	20-02-1992
WO 9837915 A	03-09-1998	AU 6084598 A	18-09-1998

**THIS PAGE BLANK (USE TO)**